var title_f20_28_20928="Nipple inversion associated with duct ectasia";
var content_f20_28_20928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nipple inversion associated with duct ectasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nipple retraction associated with duct ectasia is symmetrical and central, usually involving the nipple but not the areola.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20928=[""].join("\n");
var outline_f20_28_20928=null;
var title_f20_28_20929="Campylobacter morphology";
var content_f20_28_20929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron micrography of Campylobacter jejuni",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shadowed electron micrograph of Campylobacter jejuni showing spiral shape and long unsheathed polar flagella (the black sub- polar spots are artifacts).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Skirrow MB. Postgrad Doctor Middle East 1985; 8:50.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20929=[""].join("\n");
var outline_f20_28_20929=null;
var title_f20_28_20930="Patient information: High triglycerides (The Basics)";
var content_f20_28_20930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/48/11011\">",
"         Patient information: High cholesterol (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/43/37554\">",
"         Patient information: Medicine brand and generic names (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/24/5507\">",
"         Patient information: Metabolic syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/4/6212\">",
"         Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/56/42881\">",
"         Patient information: The metabolic syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: High triglycerides (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1825682759\">",
"      <span class=\"h1\">",
"       What are high triglycerides?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Triglycerides are fat-like substances in the blood. Everyone has them, but some people have too much of them. This can cause high levels of triglycerides in the blood, also called &ldquo;high triglycerides.&rdquo;",
"     </p>",
"     <p>",
"      Compared with people who have normal triglycerides, people with high triglycerides can have a higher risk of heart attacks, strokes, and other health problems.",
"     </p>",
"     <p>",
"      People with very high triglycerides can get inflammation in the pancreas. The pancreas is an organ that makes hormones and fluids to help the body break down food. When the pancreas gets inflamed, it can cause serious health problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1825682774\">",
"      <span class=\"h1\">",
"       What should my triglyceride level be?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ask your doctor or nurse what your triglyceride level should be. In general, levels are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Normal &ndash; less than 150",
"        <span class=\"nowrap\">",
"         mg/dL",
"        </span>",
"        (If you live outside the United States, triglycerides are measured differently. The normal level is less than 1.7",
"        <span class=\"nowrap\">",
"         mmol/L.)",
"        </span>",
"       </li>",
"       <li>",
"        Close to high &ndash; 150 to 199",
"        <span class=\"nowrap\">",
"         mg/dL",
"        </span>",
"        (1.7 to 2.2",
"        <span class=\"nowrap\">",
"         mmol/L)",
"        </span>",
"       </li>",
"       <li>",
"        High &ndash; 200 to 499",
"        <span class=\"nowrap\">",
"         mg/dL",
"        </span>",
"        (2.3 to 5.6",
"        <span class=\"nowrap\">",
"         mmol/L)",
"        </span>",
"       </li>",
"       <li>",
"        Very high &ndash; greater than 500",
"        <span class=\"nowrap\">",
"         mg/dL",
"        </span>",
"        (5.7",
"        <span class=\"nowrap\">",
"         mmol/L)",
"        </span>",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1825682791\">",
"      <span class=\"h1\">",
"       What should I do if my doctor tells me I have high triglycerides?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ask your doctor what your total risk of heart attacks and strokes is. Having high triglycerides is just 1 of many things that can increase your risk of heart attacks and strokes. You are also at higher risk if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Smoke cigarettes",
"       </li>",
"       <li>",
"        Have high blood pressure",
"       </li>",
"       <li>",
"        Are overweight",
"       </li>",
"       <li>",
"        Have a parent, sister, or brother who got heart disease at a young age (Young, in this case, means younger than 55 for men and younger than 65 for women.)",
"       </li>",
"       <li>",
"        Are a man - Women are at risk too, but men have a higher risk.",
"       </li>",
"       <li>",
"        Are older",
"       </li>",
"       <li>",
"        Have diabetes - Especially if you cannot control your blood sugar well.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1825682806\">",
"      <span class=\"h1\">",
"       Should I take medicine to lower my triglycerides?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not everyone who has high triglycerides needs medicines to lower them. Your doctor or nurse will decide if you need medicine. It depends on your age, family history, and other health concerns. People who already have a condition called &ldquo;coronary heart disease&rdquo; almost always need to take medicine for high triglycerides.",
"     </p>",
"     <p>",
"      Medicines can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to lower triglyceride levels &ndash; These include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?37/61/38868?source=see_link\">",
"         fenofibrate",
"        </a>",
"        (sample brand names: Antara&reg;, Fenoglide&reg;), nicotinic acid (sample brand names: Niacor&reg;, Niaspan&reg;), or fish oil (brand name: Lovaza&reg;).",
"       </li>",
"       <li>",
"        Statins &ndash; These medicines can reduce the risk of a heart attack or stroke. They are used to lower cholesterol levels in the body. Many people with high triglycerides also have high cholesterol.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The medicine you take will depend on your triglyceride levels and other factors. If your triglycerides are very high, you might need more than 1 medicine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1825682823\">",
"      <span class=\"h1\">",
"       Can I lower my triglycerides without medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, you might be able to lower high triglycerides if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lose weight (if you are overweight)",
"       </li>",
"       <li>",
"        Get regular exercise",
"       </li>",
"       <li>",
"        Avoid foods and drinks with a lot of sugar and carbohydrates - These include white bread, fruit juice, soda, and sweets.",
"       </li>",
"       <li>",
"        Avoid red meat, butter, fried foods, cheese, oils, and nuts &ndash; This can help if your triglycerides are over 500.",
"       </li>",
"       <li>",
"        Limit alcohol &ndash; In you are a man, have 2 drinks a day or less. If you are a woman, have 1 drink a day or less. If your triglycerides are over 500, ask your doctor or nurse if it is safe to drink alcohol.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1825682840\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=see_link\">",
"       Patient information: High cholesterol (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/24/5507?source=see_link\">",
"       Patient information: Metabolic syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=see_link\">",
"       Patient information: Medicine brand and generic names (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"       Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/56/42881?source=see_link\">",
"       Patient information: The metabolic syndrome (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/28/20930?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86012 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20930=[""].join("\n");
var outline_f20_28_20930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1825682759\">",
"      What are high triglycerides?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1825682774\">",
"      What should my triglyceride level be?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1825682791\">",
"      What should I do if my doctor tells me I have high triglycerides?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1825682806\">",
"      Should I take medicine to lower my triglycerides?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1825682823\">",
"      Can I lower my triglycerides without medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1825682840\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=related_link\">",
"      Patient information: Medicine brand and generic names (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/24/5507?source=related_link\">",
"      Patient information: Metabolic syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/56/42881?source=related_link\">",
"      Patient information: The metabolic syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_28_20931="Mineral oil: Pediatric drug information";
var content_f20_28_20931=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mineral oil: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"    see \"Mineral oil: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/46/33508?source=see_link\">",
"    see \"Mineral oil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2605148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fleet&reg; Mineral Oil Enema [OTC];",
"     </li>",
"     <li>",
"      Kondremul&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Lubricant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"      see \"Mineral oil: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 5-11 years: 5-15 mL once daily or in divided doses; should not be used for longer than 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: 2-11 years: 30-60 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 15-45 mL/day once daily or in divided doses; should not be used for longer than 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: Contents of one retention enema (range 60-150 mL)/day as a single dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2605182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Microemulsion, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kondremul&reg;: 2.5 mL/5 mL (480 mL) [sugar free; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, oral: 100% (30 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, oral [heavy]: 100% (480 mL, 3840 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, rectal [enema]: 100% per 118 mL delivered dose (133 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Mineral Oil Enema: 100% per 118 mL delivered dose (133 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical: 100% (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical [light]: 100% (3840 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2605150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: oil",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Nonemulsified mineral oil may be administered at bedtime on an empty stomach; emulsified mineral oil should be shaken before using; may be administered with meals (more palatable than nonemulsified mineral oil)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: Gently insert enema tip into rectum with a slight side-to-side movement with tip pointing toward the navel; have patient bear down",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of constipation, to relieve fecal impaction, preparation for bowel studies or surgery",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9959247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2605163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Lipid pneumonitis with aspiration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Large doses may cause anal leakage causing anal itching, hemorrhoids, irritation, perianal discomfort, soiling of clothes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with a colostomy or an ileostomy, appendicitis, ulcerative colitis, diverticulitis, dysphagia or hiatal hernia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral form should be avoided in children &lt;4 years of age because of the risk of aspiration",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2605165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Mineral Oil may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, mineral oil may impair the absorption of fat-soluble vitamins.  Management: Avoid concomitant oral administration of mineral oil and multivitamins when possible; consider separating the administration of these agents by several hours to minimize the risk of interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phytonadione: Mineral Oil may decrease the serum concentration of Phytonadione. Specifically, mineral oil may decrease the absorption of phytonadione.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Mineral Oil may decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs.  Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcipotriene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1048671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May decrease absorption of fat-soluble vitamins, carotene, calcium, and phosphorus",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The use of mineral oil for the treatment of constipation in pregnancy is not recommended (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evacuation of stool; anal leakage indicates dose too high or need for disimpaction",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Eases passage of stool by decreasing water absorption, softens stool, and lubricates the intestine",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1048667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: &sim;6-8 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Minimal following oral or rectal administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Into intestinal mucosa, liver, spleen, and mesenteric lymph nodes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/46/33508?source=see_link\">",
"      see \"Mineral oil: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take if experiencing abdominal pain, nausea, or vomiting. Rectal enema: Do not take if experiencing rectal bleeding",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baker SS, Liptak GS, Colletti RB, et al, &ldquo;A Medical Position Statement of the North American Society for Pediatric Gastroenterology and Nutrition; Constipation in Infants and Children: Evaluation and treatment,&rdquo; www.naspgn.org/constipation, 2000, 1-34.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/28/20931/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12614 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-8C00B56BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20931=[""].join("\n");
var outline_f20_28_20931=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605148\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048662\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048656\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605182\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605150\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048665\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048664\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9959247\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605163\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048669\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048655\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299716\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605165\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048671\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287015\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048661\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048654\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048667\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048668\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048660\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12614\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12614|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=related_link\">",
"      Mineral oil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/46/33508?source=related_link\">",
"      Mineral oil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_28_20932="Hydrocephalus PI";
var content_f20_28_20932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Hydrocephalus treated with a shunt",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 641px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hydrocephalus is a condition that causes too much spinal fluid to build up in the brain. Spinal fluid is fluid that surrounds and protects the brain and spinal cord. Normally, spinal fluid moves through the brain and drains into the bloodstream (see Normal brain on right). In a person with hydrocephalus, the fluid does not drain normally, or the body makes too much fluid. Doctors treat hydrocephalus with a shunt. A shunt is a long, flexible tube that a surgeon puts into a fluid-filled space inside the brain. The tube is placed under the skin and empties into the belly or heart. The shunt helps drain the extra spinal fluid from the brain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20932=[""].join("\n");
var outline_f20_28_20932=null;
var title_f20_28_20933="Obstructed umbilical cord";
var content_f20_28_20933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Umbilical cord obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The umbilical cord is excessively long (&gt;85 cm), hypertwisted (&gt;5 coils/cm), and shows red discoloration due to degenerative changes accompanying fetal death.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Raymond W. Redline, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20933=[""].join("\n");
var outline_f20_28_20933=null;
var title_f20_28_20934="Diagnostic approach to hypercalcemia";
var content_f20_28_20934=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to hypercalcemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20934/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20934/contributors\">",
"     Elizabeth Shane, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20934/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20934/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20934/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20934/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/28/20934/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is a relatively common clinical problem. Among all causes of hypercalcemia, primary hyperparathyroidism and malignancy are the most common, accounting for greater than 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Therefore, the diagnostic approach to hypercalcemia typically involves distinguishing between the two.",
"   </p>",
"   <p>",
"    It is usually not difficult to differentiate between them. Malignancy is often evident clinically by the time it causes hypercalcemia, and patients with hypercalcemia of malignancy usually have higher calcium concentrations and are more symptomatic from hypercalcemia than individuals with primary hyperparathyroidism. Although hypercalcemia in otherwise healthy outpatients is usually due to primary hyperparathyroidism and malignancy is more often responsible for hypercalcemia in hospitalized patients, other potential causes of hypercalcemia must be considered (",
"    <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic card will review the diagnostic approach to hypercalcemia. The clinical manifestations, etiology, and treatment are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERPRETATION OF SERUM CALCIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;In almost all patients, hypercalcemia is due to an elevation in the physiologically important ionized (or free) calcium concentration. However, 40 to 45 percent of the calcium in serum is bound to protein, principally albumin; as a result, increased protein binding can cause an elevation in the serum total calcium concentration without any rise in the serum ionized calcium concentration. Patients in whom this can occur include those with hyperalbuminemia due to severe dehydration and rare patients with multiple myeloma who have a calcium-binding paraprotein. This phenomenon is called pseudohypercalcemia (or factitious hypercalcemia), since the patient has a normal ionized serum calcium concentration.",
"   </p>",
"   <p>",
"    Alternatively, in patients with hypoalbuminemia due to chronic illness or malnutrition, total serum calcium concentration may be normal when serum ionized calcium is elevated. Thus, in patients with hypo- or hyperalbuminemia, the measured calcium concentration should be corrected for the abnormality in albumin (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?17/35/17969?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or for standard units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?14/51/15153?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). If a laboratory known to measure ionized calcium reliably is available, some authorities prefer to measure the serum ionized calcium in this situation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23685?source=see_link\">",
"     \"Relation between total and ionized serum calcium concentration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a single elevated serum calcium concentration should be repeated to confirm the diagnosis. If available, previous values for serum calcium should also be reviewed. The presence of longstanding asymptomatic hypercalcemia is more suggestive of primary hyperparathyroidism and also raises the much less common possibility of familial hypocalciuric hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of hypercalcemia also may be useful diagnostically. Primary hyperparathyroidism is often associated with borderline or mild hypercalcemia (serum calcium concentration often below 11",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.75",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    Values above 13",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.25",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are unusual in primary hyperparathyroidism, although they do occur, and are more common in patients with malignancy-associated hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the signs and symptoms of hypercalcemia are similar regardless of the etiology, there are several features of the clinical evaluation that may help to differentiate the etiology of hypercalcemia. Clinical findings that favor the diagnosis of primary hyperparathyroidism include an asymptomatic patient with chronic hypercalcemia, a postmenopausal woman, a normal physical examination, no other obvious cause of hypercalcemia (such as sarcoidosis), a family history of hyperparathyroidism, and evidence of multiple endocrine neoplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Definition and genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with hypercalcemia of malignancy often have higher concentrations of and more rapid increases in serum calcium and subsequently are more symptomatic (",
"    <a class=\"graphic graphic_table graphicRef54647 \" href=\"UTD.htm?41/50/42795\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    .) In addition, patients with this disorder typically have advanced disease and a poor prognosis.",
"   </p>",
"   <p>",
"    A review of diet and medications (prescription and nonprescription drugs, herbal preparations, calcium and vitamin supplements) is important to assess for the milk alkali syndrome and drug-induced hypercalcemia (",
"    <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link&amp;anchor=H13#H13\">",
"     \"Etiology of hypercalcemia\", section on 'Miscellaneous causes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27094?source=see_link\">",
"     \"The milk-alkali syndrome\"",
"    </a>",
"    .) If possible, any medication that may be causing hypercalcemia should be discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial goal of the laboratory evaluation is to differentiate parathyroid hormone (PTH)-mediated hypercalcemia (primary hyperparathyroidism and familial hyperparathyroid syndromes) from non-PTH mediated hypercalcemia (primarily malignancy, vitamin D intoxication, granulomatous disease) (",
"    <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"     table 1",
"    </a>",
"    ). Thus, once hypercalcemia is confirmed, the next step is measurement of serum PTH (",
"    <a class=\"graphic graphic_algorithm graphicRef51698 \" href=\"UTD.htm?31/46/32495\">",
"     algorithm 1",
"    </a>",
"    ). An elevated or high-normal value indicates primary hyperparathyroidism (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Parathyroid hormone'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    There appears to be a higher incidence of primary hyperparathyroidism in patients with malignancy than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Thus, despite the increased cost, it is reasonable to order an intact PTH assay as part of the routine evaluation for hypercalcemia even in a patient with known malignant disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link&amp;anchor=H9#H9\">",
"     \"Hypercalcemia of malignancy\", section on 'Coexisting primary hyperparathyroidism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the presence of low serum PTH concentrations (&lt;20",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    parathyroid hormone-related peptide (PTHrp) and vitamin D metabolites should be measured to assess for hypercalcemia of malignancy and vitamin D intoxication. If PTHrp and vitamin D metabolites are also low, another source for the hypercalcemia must be considered (",
"    <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"     table 1",
"    </a>",
"    ). Additional laboratory data (including serum protein electrophoresis for possible multiple myeloma, TSH, vitamin A) will often lead to the correct diagnosis (",
"    <a class=\"graphic graphic_algorithm graphicRef51698 \" href=\"UTD.htm?31/46/32495\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Parathyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of intact PTH (first-generation immunoradiometric assay) remains the current standard for diagnosis of hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=see_link\">",
"     \"Parathyroid hormone assays and their clinical use\"",
"    </a>",
"    .) A frankly elevated PTH concentration in the setting of hypercalcemia is likely the result of primary hyperparathyroidism (",
"    <a class=\"graphic graphic_figure graphicRef50252 \" href=\"UTD.htm?33/8/33935\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ten to 20 percent of patients with primary hyperparathyroidism have a serum PTH concentration in the upper end of the normal range; such a \"normal\" level (ie, not suppressed but not frankly elevated) is also virtually diagnostic of primary hyperparathyroidism, since it is still inappropriately high considering the presence of hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/5\">",
"     5",
"    </a>",
"    ]. However, in this circumstance, the diagnosis of familial hypocalciuric hypercalcemia also should be considered, and urinary calcium excretion (24 hour urinary calcium or calcium to creatinine ratio) should be measured. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Other tests'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Tests to confirm primary hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A low or low-normal serum intact PTH level (below 20",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    is most consistent with non-PTH-mediated hypercalcemia (",
"    <a class=\"graphic graphic_figure graphicRef50252 \" href=\"UTD.htm?33/8/33935\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"     table 1",
"    </a>",
"    ). While it is unusual for a patient with proven primary hyperparathyroidism to have a serum PTH concentration in the lower half of the normal range, it may occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Measurement of PTH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     PTH-related protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humoral hypercalcemia of malignancy is one of the most common causes of non-PTH-mediated hypercalcemia. It should be particularly suspected if there is clinical evidence of malignancy, usually a solid tumor, and the hypercalcemia is of relatively recent onset. Thus, if the patient has longstanding hypercalcemia and a low serum PTH, one should consider one of the other non-PTH mediated disorders rather than a malignancy (",
"    <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnosis of humoral hypercalcemia of malignancy can be confirmed by demonstrating an elevated serum concentration of PTH-related protein (PTHrp) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/3\">",
"     3",
"    </a>",
"    ], which is the primary mediator of hypercalcemia in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/6\">",
"     6",
"    </a>",
"    ]. However, this assay is usually not necessary for diagnosis since most patients have clinically apparent malignancy. Levels of PTH and 1,25-dihydroxyvitamin D (calcitriol) are usually appropriately suppressed in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/3,7,8\">",
"     3,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PTHrp is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link&amp;anchor=H5#H5\">",
"     \"Hypercalcemia of malignancy\", section on 'PTH-related protein'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vitamin D metabolites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum concentrations of the vitamin D metabolites, 25-hydroxyvitamin D (calcidiol) and 1,25-dihydroxyvitamin D (calcitriol), should be measured if there is no obvious malignancy and neither PTH nor PTHrp levels are elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An elevated serum concentration of 25-hydroxyvitamin D (25OHD) is indicative of vitamin D intoxication due to the ingestion of either vitamin D or calcidiol itself [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Although the serum concentration of 25OHD at which hypercalcemia typically occurs is undefined, many experts define vitamin D intoxication as a value &gt;150",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (374",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, increased levels of 1,25-dihydroxyvitamin D may be induced by direct intake of this metabolite, extrarenal production in granulomatous diseases or lymphoma, or increased renal production that can be induced by primary hyperparathyroidism but not by PTHrp [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"       \"Hypercalcemia in granulomatous diseases\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with elevated 1,25-dihydroxyvitamin D, chest x-ray (looking for malignancy or sarcoidosis) may be helpful. Patients with granulomatous disease or lymphoma generally have widespread pulmonary and extrapulmonary disease. In the absence of such involvement, a systematic search for occult pulmonary, renal, hepatic, ocular, and bone marrow granulomas is indicated when no other cause for increased 1,25-dihydroxyvitamin D is apparent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of low serum levels of PTH, PTHrp, and low or normal vitamin D metabolites suggests some other source for the hypercalcemia. In the absence of malignancy or increased PTHrp, unsuspected stimulation of bone resorption (as with multiple myeloma, thyrotoxicosis, immobilization, or vitamin A toxicity) and unrecognized calcium intake in the face of renal insufficiency (as in the milk-alkali syndrome) are the most likely candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    .) Additional laboratory data (including serum and urinary protein electrophoresis for possible multiple myeloma, TSH, vitamin A) will often provide the correct diagnosis.",
"   </p>",
"   <p>",
"    Measurement of the serum phosphate concentration and urinary calcium excretion also may be helpful in selected cases (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2631?source=see_link\">",
"     \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"    </a>",
"    ). Hyperparathyroidism and humoral hypercalcemia of malignancy (due to PTH-related protein) may be associated with frank hypophosphatemia or low-normal serum phosphate levels resulting from inhibition of renal proximal tubular phosphate reabsorption. In comparison, the serum phosphate concentration is normal or elevated in granulomatous diseases, vitamin D intoxication, immobilization, thyrotoxicosis, milk-alkali syndrome, and metastatic bone disease. The serum phosphate concentration is variable in familial hypocalciuric hypercalcemia.",
"   </p>",
"   <p>",
"    Urinary calcium excretion is usually raised or high-normal in hyperparathyroidism and hypercalcemia of malignancy. In contrast, there are three disorders in which an increase in renal calcium reabsorption leads to relative hypocalciuria (less than 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [2.5",
"    <span class=\"nowrap\">",
"     mmol/day]):",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The milk-alkali syndrome in which the associated metabolic alkalosis enhances calcium reabsorption via an uncertain mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20934/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27094?source=see_link\">",
"       \"The milk-alkali syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thiazide diuretics, which directly enhance active calcium reabsorption in the distal tubule. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"       \"Diuretics and calcium balance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Familial hypocalciuric hypercalcemia in which the fractional excretion of calcium is often less than 1 percent. Two other clues to the possible presence of this disorder are a family history of hypercalcemia and few (if any) hypercalcemic symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"       \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other tests that may also be helpful in selected cases are the serum chloride concentration and bone x-rays. A serum chloride concentration above 103",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (associated with a mild fall in the serum bicarbonate concentration) is consistent with primary hyperparathyroidism, while a lower serum chloride concentration and metabolic alkalosis are characteristic of the milk-alkali syndrome. Evidence of osteitis fibrosa on bone films is very specific for primary hyperparathyroidism but is only seen in about 5 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     AFTER DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for hypercalcemia should be aimed at lowering the serum calcium concentration and, if possible, correcting or decreasing the underlying disease. Effective treatments are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"     \"Hypercalcemia in granulomatous diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to hypercalcemia typically involves clinical evaluation and laboratory testing to distinguish between primary hyperparathyroidism and malignancy, which together account for greater than 90 percent of cases. The remaining 10 percent of patients with hypercalcemia may have one of many causes (",
"    <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"     table 1",
"    </a>",
"    ) that must be systematically considered and evaluated (",
"    <a class=\"graphic graphic_algorithm graphicRef51698 \" href=\"UTD.htm?31/46/32495\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum calcium should be corrected for albumin and an elevated concentration should be confirmed by repeat sampling. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Interpretation of serum calcium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical evaluation, including duration of hypercalcemia, presence or absence of symptoms, family history, and medications, may help determine the etiology of hypercalcemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurement of intact parathyroid hormone (PTH) is important to distinguish PTH-mediated from non-PTH-mediated causes of hypercalcemia. A frankly elevated PTH concentration or a PTH value in the upper half of the normal range in the setting of hypercalcemia is likely the result of primary hyperparathyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link\">",
"       \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PTH concentrations below 20",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      in the setting of hypercalcemia are usually not consistent with primary hyperparathyroidism and indicate the need for evaluation for other causes of hypercalcemia (",
"      <a class=\"graphic graphic_table graphicRef66865 \" href=\"UTD.htm?28/40/29324\">",
"       table 1",
"      </a>",
"      ). This evaluation should include measurement of PTH-related peptide (PTHrp) and vitamin D metabolites. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'PTH-related protein'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Vitamin D metabolites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the diagnosis is still not clear, other tests should be considered, including TSH, SPEP, UPEP, and vitamin A. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of hypercalcemia is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20934/abstract/1\">",
"      Lafferty FW. Differential diagnosis of hypercalcemia. J Bone Miner Res 1991; 6 Suppl 2:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20934/abstract/2\">",
"      Burtis WJ, Wu TL, Insogna KL, Stewart AF. Humoral hypercalcemia of malignancy. Ann Intern Med 1988; 108:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20934/abstract/3\">",
"      Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet 1992; 339:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20934/abstract/4\">",
"      Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20934/abstract/5\">",
"      Endres DB, Villanueva R, Sharp CF Jr, Singer FR. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 1991; 37:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20934/abstract/6\">",
"      Rosol TJ, Capen CC. Mechanisms of cancer-induced hypercalcemia. Lab Invest 1992; 67:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20934/abstract/7\">",
"      Schilling T, Pecherstorfer M, Blind E, et al. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab 1993; 76:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20934/abstract/8\">",
"      Kremer R, Shustik C, Tabak T, et al. Parathyroid-hormone-related peptide in hematologic malignancies. Am J Med 1996; 100:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20934/abstract/9\">",
"      Kimball S, Vieth R. Self-prescribed high-dose vitamin D3: effects on biochemical parameters in two men. Ann Clin Biochem 2008; 45:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20934/abstract/10\">",
"      Jacobus CH, Holick MF, Shao Q, et al. Hypervitaminosis D associated with drinking milk. N Engl J Med 1992; 326:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20934/abstract/11\">",
"      Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20934/abstract/12\">",
"      Beall DP, Scofield RH. Milk-alkali syndrome associated with calcium carbonate consumption. Report of 7 patients with parathyroid hormone levels and an estimate of prevalence among patients hospitalized with hypercalcemia. Medicine (Baltimore) 1995; 74:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 836 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20934=[""].join("\n");
var outline_f20_28_20934=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERPRETATION OF SERUM CALCIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Parathyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PTH-related protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vitamin D metabolites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AFTER DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/836\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/836|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/46/32495\" title=\"algorithm 1\">",
"      Diagnostic approach hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/836|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/8/33935\" title=\"figure 1\">",
"      PTH and calcium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/836|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/40/29324\" title=\"table 1\">",
"      Causes hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/50/42795\" title=\"table 2\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?17/35/17969?source=related_link\" title=\"calculator 1\">",
"      Calculator: Calcium correction in hypoalbuminemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?14/51/15153?source=related_link\" title=\"calculator 2\">",
"      Calculator: Calcium correction in hypoalbuminemia (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2631?source=related_link\">",
"      Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=related_link\">",
"      Classification and genetics of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Definition and genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21416?source=related_link\">",
"      Parathyroid hormone assays and their clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23685?source=related_link\">",
"      Relation between total and ionized serum calcium concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27094?source=related_link\">",
"      The milk-alkali syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_28_20935="Continuous venovenous hemodialysis: Technical considerations";
var content_f20_28_20935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Continuous venovenous hemodialysis: Technical considerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20935/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20935/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20935/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20935/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20935/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20935/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/28/20935/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The continuous renal replacement therapies (CRRT) comprise a spectrum of treatments that include both hemofiltration (convection-based solute and water removal) and hemodialysis (diffusion-based solute removal) techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38516?source=see_link\">",
"     \"Continuous renal replacement therapies: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These techniques have gained favor in the treatment of critically ill patients with renal failure primarily because of improved hemodynamic stability compared to intermittent hemodialysis. Although some investigators have suggested that the use of CRRT is associated with improved outcomes in acute renal failure, this has not yet been demonstrated by prospective randomized trials.",
"   </p>",
"   <p>",
"    CRRT techniques initially utilized arteriovenous extracorporeal circuits in which blood flow was driven by the gradient between the mean arterial pressure and venous pressure. Continuous venovenous hemodialysis (CVVHD) was developed in the mid-1980s as an alternative to continuous arteriovenous hemofiltration (CAVH) and continuous arteriovenous hemodialysis (CAVHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/3\">",
"     3",
"    </a>",
"    ]. The use of a pump-driven venovenous circuit in CVVHD permits blood flows that are both higher and more constant than provided by an arteriovenous circuit. In addition, the elimination of the need for a large bore arterial catheter eliminates the associated risks of arterial thrombosis and arterial bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technical aspects of performing CVVHD are reviewed here. General discussions of CRRT and the technical aspects of other modalities are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37303?source=see_link\">",
"     \"Continuous arteriovenous hemodialysis: Technical considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=see_link\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioaccess in CVVHD is generally achieved using a standard double-lumen hemodialysis catheter (",
"    <a class=\"graphic graphic_figure graphicRef63514 \" href=\"UTD.htm?27/48/28430\">",
"     figure 1",
"    </a>",
"    ). Blood flow through the extracorporeal circuit is driven by a blood pump, with rates usually maintained between 100 and 250",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Dialysate is perfused through the",
"    <span class=\"nowrap\">",
"     hemofilter/hemodialyzer,",
"    </span>",
"    countercurrent to the direction of blood flow.",
"   </p>",
"   <p>",
"    Because of the use of a blood pump, a variety of safety monitors need to be incorporated into the CVVHD circuit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since the use of a blood pump creates a risk for venous air embolism, an air-detector with an automatic pump shut-off and an occlusion clamp on the venous blood return line is an absolute requirement.",
"     </li>",
"     <li>",
"      Pressure transducers on the arterial and venous lines, although not an absolute requirement, are highly recommended. Pressure monitoring permits the detection of clotting and catheter malfunction; in the absence of such monitors, continued operation of the blood pump in the setting of undetected occlusion of the circuit may result in rupture of the dialyzer or tubing. Absolute parameters to guide therapy cannot be established, as they will vary depending upon catheter, tubing diameter, and pump speed. Specific parameters need to be established for individual systems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial descriptions of CVVHD utilized individual components rather than an integrated system. Blood flow was maintained using a freestanding blood pump. Dialysate inflow and outflow were regulated using infusion pumps (",
"    <a class=\"graphic graphic_figure graphicRef51946 \" href=\"UTD.htm?42/47/43760\">",
"     figure 2",
"    </a>",
"    ). In the absence of a balancing system, this technology did not provide precise regulation of ultrafiltration.",
"   </p>",
"   <p>",
"    Currently,",
"    <strong>",
"     multiple",
"    </strong>",
"    integrated systems for performing CVVHD are commercially available in the United States. CVVHD can also be performed using standard dialysis machines that have been modified for reduced dialysate flow rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33530?source=see_link\">",
"     \"Sustained low efficiency or extended daily dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VASCULAR ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioaccess is generally established using standard double-lumen dialysis catheters in the internal jugular, subclavian, or femoral veins. Although prolonged cannulation of the femoral vein is generally associated with an increased risk of infection, a recent randomized controlled trial did not demonstrate an increased rate of infection with femoral dialysis catheters as compared to internal jugular catheters in non-obese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The avoidance of subclavian venous catheters to prevent venous stenosis and preserve the upper extremities for future arteriovenous fistulas is not a significant issue. The mortality of patients requiring CVVHD is high, and the majority of patients who survive recover renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HEMODIALYZER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the artificial kidney device used for CVVHD is frequently referred to as a \"hemofilter,\" the term \"hemodialyzer\" is more accurate in describing the use of a membrane for diffusive solute transport. Essentially, any hemodialyzer or hemofilter that provides sufficient diffusive solute clearance may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In general, synthetic, biocompatible membranes are preferred over cellulosic membranes, as the latter have been associated with impaired recovery and survival in intermittent hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most dialysis membranes can be used, certain membranes designed for hemofiltration (for example certain polyamide membranes, such as the Gambro FH66) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/8\">",
"     8",
"    </a>",
"    ] or as hemoconcentrators for cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO) have poor diffusive solute flux, and are not suitable for CVVHD. Given these considerations, we recommend the use of any synthetic membrane suitable for hemodialysis, however, AN-69 membranes should be used with caution in patients being treated with angiotensin converting enzyme inhibitors, because of an increased incidence of anaphylactoid reactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link&amp;anchor=H4#H4\">",
"     \"Reactions to the hemodialysis membrane\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIALYSATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The composition of the dialysis fluid should approximate normal plasma composition. The issues regarding dialysate composition are the same with CVVHD as for CAVHD. A detailed discussion of these may be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37303?source=see_link\">",
"     \"Continuous arteriovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although many of the early descriptions of CRRT used lactate-buffered dialysate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    replacement fluids, subsequent studies have suggested benefit to the use of bicarbonate-buffered fluids. Healthy individuals are able to metabolize approximately 100 mmol per hour of lactate, generating an equimolar amount of bicarbonate.",
"   </p>",
"   <p>",
"    Although lactate metabolism may be impaired in acutely ill patients, the use of lactate-buffered solutions is effective for control of acidosis in both continuous hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/8,10\">",
"     8,10",
"    </a>",
"    ] and continuous hemofiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/11\">",
"     11",
"    </a>",
"    ]. However, in a non-randomized crossover cohort study of 54 patients, better control of systemic acidemia was observed using lactate-free dialysate (bicarbonate concentration 24.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    than during CAVHD using lactate-buffered (30",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/12\">",
"     12",
"    </a>",
"    ]. There was also an associated mean decline in mean arterial blood pressure of 2.7 mmHg with lactate-buffered dialysate as compared to an increase in MAP of 5.8 mmHg using lactate-free dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/12\">",
"     12",
"    </a>",
"    ]. Another study reported increased cardiovascular instability observed using lactate-buffered replacement fluids in CVVH, compared to bicarbonate-buffered replacement fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/13\">",
"     13",
"    </a>",
"    ]. However, neither study demonstrated differences in survival or recovery of renal function related to the buffer selection in the absence of lactic acidosis.",
"   </p>",
"   <p>",
"    Bicarbonate buffered dialysate is required for patients with impaired lactate metabolism who are intolerant of the lactate load provided by lactate-buffered dialysate. Lactate accumulation is associated with alterations in the NADH:NAD ratio, increased protein catabolism, increased urea generation, and myocardial depression. In a series of 200 patients with lactic acidosis undergoing CRRT, improved survival was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, the absence of commercially available bicarbonate-buffered dialysis solutions for use in CVVHD led to a variety of strategies for the preparation of dialysate. Sterile bicarbonate-buffered dialysate may be prepared at the time of use by the admixture of intravenous solutions to achieve final concentrations (",
"    <a class=\"graphic graphic_table graphicRef75357 \" href=\"UTD.htm?12/26/12715\">",
"     table 1",
"    </a>",
"    ). However, frequent errors in the compounding of these solutions have been described, including some that have led to patient fatalities [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The preparation of bicarbonate-buffered dialysate using the proportioning system of a standard single-pass hemodialysis machine followed filtration of the dialysate to ensure bacteriologic sterility has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the past, due to the instability of bicarbonate when stored for prolonged periods in gas-permeable infusion bags, only lactate-buffered solutions were commercially available as dialysate in CRRT; however, there are now",
"    <strong>",
"     multiple",
"    </strong>",
"    bicarbonate-buffered fluids available in the United States. A variety of different electrolyte compositions are available, which allows tailoring of the prescription to individual patient need.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clotting of the extracorporeal system is the most common factor that contributes to ineffective treatment during CVVHD. Anticoagulation is generally required to maintain system patency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is the most commonly used anticoagulant. Typically, a bolus dose of 500 to 2000 units of heparin is administered into the inflow (\"arterial\") limb of the extracorporeal circuit followed by a continuous infusion of between 300 to 500 units per hour. Therapy may be monitored by following the partial thromboplastin time in the venous limb; the heparin dose should be titrated to maintain a value of 1.5 to 2.0 times control. Larger doses of heparin may be required in patients with recurrent system clotting. Its discontinuation may be necessary if clinical bleeding or severe thrombocytopenia develops. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Citrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional citrate anticoagulation has been widely used as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. With this regimen, sodium citrate is infused into the inflow (\"arterial\") limb of the extracorporeal circuit, chelating calcium and thereby inhibiting clotting. Intravenous calcium must be infused systemically to maintain a normal ionized serum calcium concentration. The regimens used are essentially the same as those used for CAVHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37303?source=see_link\">",
"     \"Continuous arteriovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of citrate anticoagulation may require modification of the dialysate composition. Since the citrate provides an alkali load, buffers (eg, bicarbonate, lactate) need to be reduced in concentration or deleted from the dialysate. The dialysate should also be calcium free, to prevent reversal of the citrate effect in the extracorporeal circuit. If a hypertonic citrate solution is used, the sodium concentration in the dialysate must be reduced to prevent the development of hypernatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, CVVHD was originally performed using individual component parts. A conventional variable-speed roller blood-pump was used to maintain blood flow. A bubble trap with an air bubble detector was placed in the return line to prevent air embolism. The air detector was connected to the blood-pump and a return line clamp. Triggering the air detector immediately stopped the blood-pump and clamped the return line. The dialysate inflow and outflow was controlled by infusion pumps. Since the difference between dialysate inflow and outflow is net ultrafiltration, small errors in the delivered flow by either pump could result in substantial errors in net ultrafiltration. Commonly, intravenous infusion pumps which are not designed to operate against pressure gradients were used to control dialysate inflow and outflow. Since significant pressure developed in the hemodialyzer dialysate compartment during treatment, there was decreased delivery of dialysate by the inflow pump and augmented flow across the outflow pump [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even small errors in flow rates could result in large fluid balance errors. At flow rates of 2 liters per hour, a 2 percent error by each pump (40",
"    <span class=\"nowrap\">",
"     mL/hour)",
"    </span>",
"    could result in excess ultrafiltration of almost 2 liters per day. These errors were greatest with linear peristaltic pumps. Piston-type volumetric pumps and roller pumps were more accurate, but were associated with rapid pressure changes in the dialysate compartment and an increased risk of fiber rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple integrated CRRT systems suitable for CVVHD are currently available in the United States (Prisma, Gambro, Lakewood, CO; PrismaFlex, Gambro, Lakewood, CO; Diapact, B. Braun, Bethlehem, PA; Aquarius, Baxter Healthcare, Deerfield, IL; and System One, NxStage Medical, Lawrence, MA). While each has slightly different features, their basic components are similar:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood flow and dialysate inflow and outflow are controlled by roller-pumps.",
"     </li>",
"     <li>",
"      Balancing systems provide ultrafiltration control.",
"     </li>",
"     <li>",
"      Dialysate inflow and outflow are continuously measured and the pump speeds adjusted to maintain the desired flow rates. Using this microprocessor driven servoregulatory control, ultrafiltration rates can be maintained with high precision.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Fresenius 2008K dialysis machine may be modified to provide a form of slow continuous hemodialysis that is analogous to CVVHD. This mode of therapy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33530?source=see_link\">",
"     \"Sustained low efficiency or extended daily dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OPERATIONAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solute removal during CVVHD is primarily by diffusion. The degree of solute equilibration between the blood and dialysate is dependent primarily upon the dialysate flow rate. For low molecular weight species, such as urea, near complete equilibration occurs at low dialysate flow rates, and decreases as dialysate flow rates increase [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/8,25,26\">",
"     8,25,26",
"    </a>",
"    ]. Over the commonly utilized range of dialysate flows (500",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    to 2,500",
"    <span class=\"nowrap\">",
"     mL/hour)",
"    </span>",
"    the relationship between dialysate flow and clearance is nearly linear (",
"    <a class=\"graphic graphic_figure graphicRef70337 \" href=\"UTD.htm?33/34/34350\">",
"     figure 3",
"    </a>",
"    ). For higher molecular weight species (eg, &szlig;2-microglobulin), equilibration is limited, and clearance plateaus or increases non-linearly with increasing dialysate flow rates [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, the impact of blood flow on solute clearance is small. There is no significant increase in urea clearance during CVVHD when dialysate flow is 2 liters per hour (33",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and blood flow is increased above 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/8\">",
"     8",
"    </a>",
"    ]. However, blood-flow dependence may be observed at high dialysate flow rates.",
"   </p>",
"   <p>",
"    Convective solute clearance is less significant, but also present, during CVVHD. To the extent that ultrafiltration occurs, convective flux will be present. This convective clearance can be estimated as the product of the membrane sieving coefficient(s) and the ultrafiltration rate.",
"   </p>",
"   <p>",
"    There is a small interaction between the convective and diffusive components of clearance. When the diffusive clearance measured in the absence of ultrafiltration is added to the convective clearance during ultrafiltration in the absence of diffusion, the sum is greater than the actual clearance observed during CVVHD with ultrafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/26\">",
"     26",
"    </a>",
"    ]. The magnitude of the interaction increases with solute molecular weight.",
"   </p>",
"   <p>",
"    In addition to the convective flux that occurs due to ultrafiltration, convective transport may also result from",
"    <span class=\"nowrap\">",
"     filtration/back-filtration.",
"    </span>",
"    When membranes with high ultrafiltration coefficients are employed, ultrafiltration occurs at the blood-inlet (\"arterial\") end of the dialyzer, since blood-side pressure exceeds dialysate pressure. Over the length of the dialyzer, blood-side pressure decreases, whereas dialysate pressure is highest at the dialysate inlet (which, due to the countercurrent orientation of dialysate and blood flow, is at the blood-outlet end of the dialyzer). Thus, at this end of the dialyzer, back-filtration of dialysate compensates for fluid previously lost through ultrafiltration. Despite minimal net ultrafiltration, the net effect is an augmentation of solute clearance due to convection. The impact of this component of convective clearance increases with solute molecular weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DOSE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose of therapy in CVVHD has not been determined. Although no studies have specifically evaluated the dose of therapy in CVVHD, several studies have evaluated outcomes with different doses with similar modalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of different doses of continuous venovenous hemofiltration (CVVH) found an improved survival when higher solute clearance rates were achieved by increasing the ultrafiltration rate [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/27\">",
"       27",
"      </a>",
"      ]. Survival at 15 days after stopping hemofiltration was 41, 57, and 58 percent in patients in whom the ultrafiltration rate was 20, 35, and 45",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour, respectively.",
"     </li>",
"     <li>",
"      A second study compared CVVH with a mean ultrafiltration rate of 25 &plusmn; 5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour to continuous venovenous hemodiafiltration (CVVHDF) in which a mean dialysate flow rate of 18 &plusmn; 5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour was added to a mean ultrafiltration rate of 24 &plusmn; 6",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/28\">",
"       28",
"      </a>",
"      ]. Survival at 28 days was significantly higher among those who underwent higher dose CVVHDF (39 and 59 percent in patients treated with CVVH and CVVHDF, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although both of these studies suggested that higher doses of therapy are of benefit, and the second study that compared CVVH to CVVHDF suggests that it does not matter whether the increase in clearance is provided using convection or diffusion, other studies have not demonstrated improved outcomes when effluent flow rates were increased beyond 20 to 25",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single center study of 200 patients, there was no improvement in survival in patients randomly assigned to high dose (35",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour) as compared to a lower dose (20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour) of CVVHDF [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The United States",
"      <span class=\"nowrap\">",
"       VA/NIH",
"      </span>",
"      Acute Renal Failure Trial Network study (ATN), which compared outcomes with two dosing strategies in 1124 patients, and found that more intensive renal support beyond that obtained with standard continuous renal replacement therapy (with an effluent flow rate of 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour) did not improve clinical outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Australia and New Zealand Intensive Care Society RENAL Study randomized 1508 patients to CVVHDF at either 25",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour or 40",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour and found no improvement in survival with more intensive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20935/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We therefore recommend that continuous renal replacement therapy (independent of form) be provided with an effluent flow rate (sum of hemofiltration rate and dialysate flow rate) of at least 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10359582\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The continuous renal replacement therapies (CRRT) comprise a spectrum of treatments that include both convection-based (hemofiltration) and diffusion-based (hemodialysis) solute removal techniques. Continuous venovenous hemodialysis (CVVHD) provides diffuse solute clearance for the management of kidney failure in critically ill patients (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To perform CVVHD, a system requires only two fluid management pumps to regulate dialysate inflow and effluent (spent dialysate plus ultrafiltrate) outflow. A number of \"integrated\" CRRT machines represent the standard of care. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Equipment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any hemodialyzer or hemofilter that provides sufficient diffusive solute clearance may be utilized for CVVHD. Synthetic, biocompatible membranes are preferred over cellulosic membranes. However AN-69 membranes should be used with caution in patients being treated with angiotensin converting enzyme inhibitors because of an increased incidence of anaphylactoid reactions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hemodialyzer'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link&amp;anchor=H4#H4\">",
"       \"Reactions to the hemodialysis membrane\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The composition of the dialysis fluid is the same as for other modalities of CRRT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37303?source=see_link\">",
"       \"Continuous arteriovenous hemodialysis: Technical considerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anticoagulation is generally required to maintain system patency.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      is the most commonly utilized anticoagulant. Regional citrate anticoagulation has been widely used as an alternative to heparin in all modalities of CRRT, including CVVHD. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The minimum delivered total effluent flow rates for CVVHD is 20 to 25",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Dose of therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/1\">",
"      Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis 1998; 32:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/2\">",
"      Mehta RL. Continuous renal replacement therapy in the critically ill patient. Kidney Int 2005; 67:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/3\">",
"      Tam PY, Huraib S, Mahan B, et al. Slow continuous hemodialysis for the management of complicated acute renal failure in an intensive care unit. Clin Nephrol 1988; 30:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/4\">",
"      Tominaga GT, Ingegno M, Ceraldi C, Waxman K. Vascular complications of continuous arteriovenous hemofiltration in trauma patients. J Trauma 1993; 35:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/5\">",
"      Bellomo R, Parkin G, Love J, Boyce N. A prospective comparative study of continuous arteriovenous hemodiafiltration and continuous venovenous hemodiafiltration in critically ill patients. Am J Kidney Dis 1993; 21:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/6\">",
"      Parienti JJ, Thirion M, M&eacute;garbane B, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA 2008; 299:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/7\">",
"      Ifediora OC, Teehan BP, Sigler MH. Solute clearance in continuous venovenous hemodialysis. A comparison of cuprophane, polyacrylonitrile, and polysulfone membranes. ASAIO J 1992; 38:M697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/8\">",
"      Relton S, Greenberg A, Palevsky PM. Dialysate and blood flow dependence of diffusive solute clearance during CVVHD. ASAIO J 1992; 38:M691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/9\">",
"      Himmelfarb J, Tolkoff Rubin N, Chandran P, et al. A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis. J Am Soc Nephrol 1998; 9:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/10\">",
"      Palevsky, P, Piraino, B, Perlmutter, J, Greenberg, A. Slow continuous ultrafiltration and dialysis for the treatment of acute renal failure. (Abstract). J Am Soc Nephrol 1991; 2:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/11\">",
"      Thomas AN, Guy JM, Kishen R, et al. Comparison of lactate and bicarbonate buffered haemofiltration fluids: use in critically ill patients. Nephrol Dial Transplant 1997; 12:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/12\">",
"      McLean AG, Davenport A, Cox D, Sweny P. Effects of lactate-buffered and lactate-free dialysate in CAVHD patients with and without liver dysfunction. Kidney Int 2000; 58:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/13\">",
"      Barenbrock M, Hausberg M, Matzkies F, et al. Effects of bicarbonate- and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients. Kidney Int 2000; 58:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/14\">",
"      Hilton PJ, Taylor J, Forni LG, Treacher DF. Bicarbonate-based haemofiltration in the management of acute renal failure with lactic acidosis. QJM 1998; 91:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/15\">",
"      Johnston RV, Boiteau P, Charlebois K, et al. Responding to tragic error: lessons from Foothills Medical Centre. CMAJ 2004; 170:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/16\">",
"      Culley CM, Bernardo JF, Gross PR, et al. Implementing a standardized safety procedure for continuous renal replacement therapy solutions. Am J Health Syst Pharm 2006; 63:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/17\">",
"      Leblanc M, Moreno L, Robinson OP, et al. Bicarbonate dialysate for continuous renal replacement therapy in intensive care unit patients with acute renal failure. Am J Kidney Dis 1995; 26:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/18\">",
"      Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/19\">",
"      Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis 2000; 35:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/20\">",
"      Cointault O, Kamar N, Bories P, et al. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions. Nephrol Dial Transplant 2004; 19:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/21\">",
"      Tolwani AJ, Campbell RC, Schenk MB, et al. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 2001; 60:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/22\">",
"      Tobe SW, Aujla P, Walele AA, et al. A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. J Crit Care 2003; 18:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/23\">",
"      Swartz R, Pasko D, O'Toole J, Starmann B. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol 2004; 61:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/24\">",
"      Roberts M, Winney RJ. Errors in fluid balance with pump control of continuous hemodialysis. Int J Artif Organs 1992; 15:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/25\">",
"      Pichette V, Leblanc M, Bonnardeaux A, et al. High dialysate flow rate continuous arteriovenous hemodialysis: a new approach for the treatment of acute renal failure and tumor lysis syndrome. Am J Kidney Dis 1994; 23:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/26\">",
"      Brunet S, Leblanc M, Geadah D, et al. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999; 34:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/27\">",
"      Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/28\">",
"      Saudan P, Niederberger M, De Seigneux S, et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int 2006; 70:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/29\">",
"      Tolwani AJ, Campbell RC, Stofan BS, et al. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol 2008; 19:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/30\">",
"      VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20935/abstract/31\">",
"      RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361:1627.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1902 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-217.16.9.173-E29AE5AA73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20935=[""].join("\n");
var outline_f20_28_20935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10359582\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VASCULAR ACCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HEMODIALYZER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIALYSATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Citrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OPERATIONAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DOSE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10359582\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1902\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1902|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/48/28430\" title=\"figure 1\">",
"      Schematic of CVVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/47/43760\" title=\"figure 2\">",
"      Apparatus for CVVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/34/34350\" title=\"figure 3\">",
"      Clear vs effluent rate CRRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1902|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/26/12715\" title=\"table 1\">",
"      Bicarbonate buffered dialysate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37303?source=related_link\">",
"      Continuous arteriovenous hemodialysis: Technical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38516?source=related_link\">",
"      Continuous renal replacement therapies: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=related_link\">",
"      Reactions to the hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33530?source=related_link\">",
"      Sustained low efficiency or extended daily dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_28_20936="Mast cells: Surface receptors and signal transduction";
var content_f20_28_20936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mast cells: Surface receptors and signal transduction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20936/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20936/contributors\">",
"     Michael Gurish, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20936/contributors\">",
"     Mariana C Castells, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20936/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20936/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20936/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20936/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/28/20936/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cells display a host of stimulatory and inhibitory surface receptors, allowing them to respond to a variety of stimuli in a modulated manner. The ultimate response of a cell to its environment is determined by the balance of stimulatory and inhibitory factors present at a given moment and acting on different receptors.",
"   </p>",
"   <p>",
"    This topic review will discuss the activating and inhibitory receptors on mast cells and signal transduction mechanisms. The information in this review pertains to human mast cells whenever possible, and notation is made when data are derived purely from murine studies. Mast cell derived mediators, as well as the development, identification, and physiologic roles of mast cells are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=see_link\">",
"     \"Mast cell derived mediators\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=see_link\">",
"     \"Mast cells: Development, identification, and physiologic roles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACTIVATING RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important stimulatory receptors on the surface of mast cells include the high affinity IgE receptor, IgG receptors, toll-like receptors, and receptors for stem cell factor, complement proteins, neuropeptides and opioids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     High affinity IgE receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical mast cell activation occurs through the high affinity IgE receptor, FcEpsilonRI (Fc&epsilon;RI). Activation occurs when adjacent receptors, occupied by receptor-bound IgE, are cross-linked by a multivalent antigen. This is a strong stimulus for degranulation and release of preformed mediators, as well as for de novo production and subsequent release of leukotrienes, prostaglandins, and cytokines, including numerous chemokines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=see_link\">",
"     \"Mast cell derived mediators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgE is involved in defense against parasitic infection and in hypersensitivity reactions. It is estimated that there are 10(4)-10(6) Fc&epsilon;RI receptors on the surface of each mast cell [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/1\">",
"     1",
"    </a>",
"    ]. As the transcript is stabilized by binding of monomeric IgE to the receptor, there is a greater number of receptors and hence capacity for binding serum IgE in atopic individuals. This likely accounts for this large range in the number of receptors per cell and the efficacy of therapy directed to reducing the serum titer of IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H174337300\">",
"     'Clinical applications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The fully functional form of the Fc&epsilon;RI receptor on mast cells and on basophils is a tetrameric structure consisting of one alpha chain, one beta chain, and two gamma chains [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The alpha chain contains two extracellular domains that bind IgE with high affinity.",
"     </li>",
"     <li>",
"      The beta chain transverses the membrane four times and may form an ion pore.",
"     </li>",
"     <li>",
"      The two gamma chains, which are structurally homologous to the zeta chain of the T-cell receptor, each have two cytoplasmic",
"      <strong>",
"       I",
"      </strong>",
"      mmunoreceptor",
"      <strong>",
"       T",
"      </strong>",
"      yrosine",
"      <strong>",
"       A",
"      </strong>",
"      ctivation",
"      <strong>",
"       M",
"      </strong>",
"      otifs (ITAMs) and mediate signal transduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other human cell types express a trimeric form of Fc&epsilon;RI, which lacks the &beta; chain. This is found on eosinophils, epithelial cells, and on antigen presenting cells, such as dendritic cells, Langerhans cells, and monocytes, and may be involved in the immune modulatory functions of these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/5,7-11\">",
"     5,7-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=see_link&amp;anchor=H15#H15\">",
"     \"Mast cells: Development, identification, and physiologic roles\", section on 'Acquired immunity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     IgG receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human mast cells also express receptors for IgG, including FcGammaRII&alpha; (FC&gamma;RII&alpha;) and Fc&gamma;RIII, activating receptors that bind IgG3 most avidly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. These allow activation of the cells by circulating or in situ formed immune complexes. Human mast cells can also transiently express Fc&gamma;RI, another activating receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Stem cell factor receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cells express c-kit, the receptor for stem cell factor, which is the critical growth factor for mast cell development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=see_link&amp;anchor=H5#H5\">",
"     \"Mast cells: Development, identification, and physiologic roles\", section on 'c-kit and SCF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For mature mast cells, SCF also serves as a chemotactic factor and can be a direct activator, causing degranulation and cysteinyl leukotriene production, and in conjunction with IL-10 and IL-1beta, can be an inducer of prostanoid and cytokine production [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/15-21\">",
"     15-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Complement receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cells in human skin express receptors for both the anaphylatoxins, C3a and C5a, and release histamine in response to exposure to these complement fragments. These provide additional mechanisms in which immune complexes or microbes may activate mast cells via classical or alternative complement pathways. However, in contrast to activation through Fc&epsilon;RI, exocytosis by complement fragments is not associated with the generation of prostaglandins or leukotrienes. There is some variability in distribution of complement receptors, as some cardiac mast cells demonstrate a functional receptor for C5a (CD88) by immunofluorescence, whereas mast cells isolated from the human lung, uterus, or tonsils do not [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=see_link&amp;anchor=H2#H2\">",
"     \"Complement pathways\", section on 'Classical pathway'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Toll-like receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cells express a variety of Toll-like receptors (TLRs), which are both surface and internal membrane-associated molecules in eukaryotic cells that detect and respond to microbial infection. The activation of mast cells through TLRs is an important mechanism through which mast cells serve as a bridge between the innate and adaptive immune systems. Using cultured human mast cell lines, these cells have been shown to express TLRs 1 through 9, although TLR8 was lost with continued culture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human mast cells also can be activated by many of the ligands specific to the different receptors (eg, peptidoglycans through TLR2, double stranded RNA through TLR3, and lipopolysaccharide (LPS) through TLR4). In broad terms, mast cells respond to activation through TLR with the production of inflammatory cytokines, rather than degranulation, yet the responses to the different stimuli are distinct. Thus, double stranded RNA induces expression of the type I interferons, but not TNF&alpha; or IL-6, while LPS induces expression of these two proinflammatory cytokines, but not degranulation as occurs following peptidoglycan stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A general discussion of toll-like receptors is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Receptors for neuropeptides and opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropeptides, such as VIP, substance P, and somatostatin mediate secretory granule exocytosis from mast cells with little generation of lipid mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. The responses to these neuropeptides are mediated through pertussis-sensitive G-proteins, with concomitant release of calcium from intracellular stores [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain muscle relaxants, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , tubocurarine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    , cause both skin and lung mast cells to release histamine, while opiates also cause histamine release from skin mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The latter underlies the common occurrence of pruritus and urticaria in response to opioid analgesics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Platelet activating factor receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Receptors for platelet activating factor (PAF) have been identified on human mast cells cultured from the lung and from progenitors in peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/40\">",
"     40",
"    </a>",
"    ]. PAF is known to be important in murine anaphylaxis, and preliminary data suggest that PAF plays a role in human anaphylaxis as well, particularly in amplification of the initial response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18778?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathophysiology of anaphylaxis\", section on 'Chemical mediators of anaphylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INHIBITORY RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cells express several inhibitory receptors. While the functions of these are not fully understood, some have been shown to regulate mast cell-mediated events, including human mast cell activation, and in the mouse, mast cell-dependent inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Many of the inhibitory receptors contain",
"    <strong>",
"     i",
"    </strong>",
"    mmunoregulatory",
"    <strong>",
"     t",
"    </strong>",
"    yrosine",
"    <strong>",
"     i",
"    </strong>",
"    nhibition",
"    <strong>",
"     m",
"    </strong>",
"    otifs (ITIMs).",
"   </p>",
"   <p>",
"    Examples of ITIM-associated receptors capable of suppressing mast cell activation are Fc&gamma;RIIb, CD300a, platelet-endothelial cell adhesion molecule 1 (PECAM-1), paired immunoglobulin-like receptor B (PIR-B), the c-lectin mast cell function-associated antigen (MAFA), sialic acid-binding immunoglobulin-like lectins (Siglecs), and leukocyte immunoglobulin-like receptor B4 (LILB4) (also known as glycoprotein 49B1) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. PIR-B is a surface receptor expressed on both mast cells and macrophages and appears to regulate basal activation of both cells. Examples of ITIM-independent inhibitory receptors include the mast cell receptor for the glycoprotein CD200, the A2b adenosine receptor, and the transient receptor potential cation channel, subfamily M, member 4 (TRPM4) ion channel [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Leukocyte immunoglobulin-like receptor 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Murine mast cells express Leukocyte immunoglobulin-like receptor 4 (LILRB4), an inhibitory receptor with significant homology with the killer cell inhibitory receptors (KIR) found on natural killer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/37,44,45\">",
"     37,44,45",
"    </a>",
"    ]. This molecule was previously called gp49B1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30889?source=see_link\">",
"     \"NK cell deficiency syndromes: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mice deficient in LILRB4 have increased severity in local and systemic anaphylaxis, suggesting that this receptor has a \"braking function\" during mast cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     CD200 receptor 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CD200 R1 receptor, a member of the immunoglobulin supergene family that is expressed on myeloid cells, inhibits mast cell degranulation and cytokine secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. It does not contain an ITIM and may play a role in determining the cell's threshold for activation. In contrast, a related member of this family, CD200 R3, has been implicated in mast cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627444214\">",
"    <span class=\"h2\">",
"     CD300a",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD300a is a type I transmembrane protein that contains three classical and one nonclassical ITIM in the intracellular cytoplasmic tail. It is expressed on both myeloid and lymphoid cells. Coligation of the high affinity IgE receptor and CD300a inhibits mast cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/51-54\">",
"     51-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Beta adrenoreceptor 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beta adrenoreceptor (&beta;-2) found on human lung mast cells is linked via a G-protein to a cAMP-dependent pathway of calcium mobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/55\">",
"     55",
"    </a>",
"    ]. Isolated human lung mast cells display inhibition of degranulation and eicosanoid generation after treatment with beta agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     IgG receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IgG receptor Fc&gamma;RIIb is an inhibitory receptor on the surface of mast cells. Fc&gamma;RIIb crosslinking has been shown to reduce IgE-mediated mast cell activation, and investigational therapies based on this mechanism have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Toll-like receptor 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;TLR4 also binds a protein produced by parasitic roundworms, ES-62 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/60\">",
"     60",
"    </a>",
"    ]. Unlike the binding of TLR4 to LPS, however, ligation with ES-62 results in inhibition of activation of the cell through Fc&epsilon;RI, and therefore TLR4 functions as an inhibitory receptor in this context [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/61\">",
"     61",
"    </a>",
"    ]. Nematodes expressing this protein would be able to modulate the mast cell inflammatory response of the host to infection, thus preventing fulminant inflammation and demise of the host or expulsion of the parasite. Future therapies based upon analogs of ES-62 have been proposed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SIGNAL TRANSDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signal transduction pathways are intertwined webs of molecules, through which external information about ongoing events is transmitted to the internal workings of that cell in order to induce a specific effect. These pathways are complex, overlapping, and tightly controlled. The signal transduction pathway that results from cross-linking of two Fc&epsilon;RI receptors by multivalent antigen on the surface of a mast cell is described here as an example:",
"   </p>",
"   <p>",
"    Cross-linking of the Fc&epsilon;RI receptor by",
"    <span class=\"nowrap\">",
"     polymeric/polyvalent",
"    </span>",
"    antigens bound to specific IgE at the membrane initiates signal transduction. Specific IgE is bound to the &alpha; chain of the Fc&epsilon;RI, while the &beta; and &gamma; chains are critical for signal transduction. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'High affinity IgE receptor'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cross-linking of Fc&epsilon;RI leads to phosphorylation of the immunoreceptor tyrosine based activation motif (ITAM) of the cytoplasmic domain of both the beta and gamma subunits of the receptor complex [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/62\">",
"     62",
"    </a>",
"    ]. The beta chain of Fc&epsilon;RI is constitutively associated with Lyn, a tyrosine kinase belonging to the Src family [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Tyrosine phosphorylation of the beta subunit activates Lyn [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/62\">",
"     62",
"    </a>",
"    ]. Activated Lyn mediates recruitment of the nonreceptor tyrosine kinase Syk, which interacts via its SH2 domain with the phosphorylated ITAM on the gamma subunit of Fc&epsilon;RI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/62,64,65\">",
"     62,64,65",
"    </a>",
"    ]. Syk then stimulates sequences leading to the mitogen-activated protein kinase (MAPK) pathways and the protein kinase C (PKC) and Ca2+ dependent pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activation of the MAPK pathway has been linked to the downstream activation of cytosolic phospholipase A2 (cPLA2) in stimulated mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. The enzyme cPLA2 translocates from a cytosolic to membrane compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/71\">",
"     71",
"    </a>",
"    ] where it cleaves arachidonic acid from phospholipids for the generation of leukotrienes and prostaglandins as well as forming lyso-phosphatidylcholine, the precursor of platelet activating factor (PAF).",
"   </p>",
"   <p>",
"    Syk phosphorylation also causes activation of phosphatidylinositol-specific phospholipase C (PLCg1). The activated PLC cleaves phosphatidylinositol-derived inositol 4,5 bisphosphate (PIP2) to generate the second messengers diacylglycerol (DAG) and inositol 1,4,5 triphosphate (IP3) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. DAG activates protein kinase C with a consequent translocation to the plasma membrane.",
"   </p>",
"   <p>",
"    PKC activation results in phosphorylation of numerous proteins including the myosin light chain, which is thought to contribute to exocytosis of mast cell granules and the activation of c-fos and c-jun, leading to enhanced transcription of immediate early genes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. IP3 acts at the endoplasmic reticulum to release calcium from intracellular stores and activates the",
"    <span class=\"nowrap\">",
"     calmodulin/calcineurin",
"    </span>",
"    phosphatase pathway with resultant transcription of cytokine genes, such as IL-6, via the nuclear translocation of the transcription factor NF-AT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Subsequent influx of calcium through the membrane further augments mast cell degranulation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early activation events lead to the release of granule contents, arachidonic acid metabolites, and TNF-&alpha; secretion. Late phase events include the release of cytokines and chemokines, such as IL-1&beta;, IL-6, and newly formed TNF-&alpha;. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=see_link\">",
"     \"Mast cell derived mediators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174337300\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activating and inhibitory receptors on mast cells and the signaling pathways used by these receptors can be manipulated to achieve specific clinical effects. The following are examples of therapeutic applications that have either already been realized or are in development:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The high affinity IgE receptor can be downregulated on the surface of mast cells by administration of the anti-IgE therapy",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      . This agent binds free IgE in the serum and tissues and clears it from circulation, resulting in a reduction in the number of high affinity IgE receptors present on mast cells (and basophils). Anti-IgE therapy is used in the treatment of allergic asthma. It has also been successfully administered to patients with hymenoptera venom-induced anaphylaxis who require venom immunotherapy, but who have reactions to the injections, to improve the safety of the vaccination process. In the future, its use may be extended to other diseases in which IgE is part of the pathophysiology, including allergic rhinitis, urticaria and anaphylaxis. The use of anti-IgE therapy in allergy asthma is reviewed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link\">",
"       \"Anti-IgE therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The receptor for stem cell factor, c-kit, is a tyrosine kinase.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      (Gleevec) is a tyrosine kinase inhibitor that preferentially targets wild type c-kit and is useful in a small number of patients with systemic mastocytosis. However, most patients with systemic mastocytosis have a mutation (D816V) in the gene for this receptor, and so are resistant to imatinib. Other tyrosine kinase inhibitors that target mutated and wild type c-kit, such as PKC410 (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      ) and PKC412 (midostaurin) are in development. Patients with aggressive forms of mastocytosis have benefited from these, providing evidence that activation of c-kit is a fundamental part of the pathophysiology of the disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment and prognosis of systemic mastocytosis\", section on 'Role of tyrosine kinase inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Analogs of the parasite product ES-62, an agonist of TLR4, are in development. The action of ES-62 at TLR4 leads to inhibition of Fc&epsilon;RI. It is hoped that these agents could be used as immunomodulators to treat or prevent allergic and other inflammatory diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/79,80\">",
"       79,80",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link&amp;anchor=H26#H26\">",
"       \"Toll-like receptors: Roles in disease and therapy\", section on 'TLR-based therapies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fusion proteins composed of major allergenic proteins linked to agonists of inhibitory IgG receptors have been developed for the purposes of treating allergic disease. For example, cat allergen FelD1 has been fused with Fc&gamma;I and is being studied for use in safer and more effective forms of immunotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20936/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Syk inhibitors have been studied to block signal transduction in mast cells and prevent activation at the time of allergen exposure, and their application in allergic rhinitis and asthma is under study. However, the potential side effects of blocking signal transduction are complex, due to the broad functions of Syk in T cells and other immune cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mast cells display a host of stimulatory and inhibitory surface receptors, and the balance of signals arising from these receptors at a given moment determines the ultimate response of the cell. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important stimulatory mast cell receptors include the high affinity IgE receptor, IgG receptors, toll-like receptors, complement component receptors, and the receptor for stem cell factor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Activating receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhibitory receptors act to regulate and modulate mast cell function. Critical inhibitory receptors include LILRB4 and CD200R1. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Inhibitory receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signal transduction pathways are complex and precisely controlled networks of molecules, through which information is transmitted from the cell surface to the inside of the cell to induce a specific effect. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Signal transduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/1\">",
"      Conrad DH, Bazin H, Sehon AH, Froese A. Binding parameters of the interaction between rat IgE and rat mast cell receptors. J Immunol 1975; 114:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/2\">",
"      MacGlashan D Jr, McKenzie-White J, Chichester K, et al. In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody. Blood 1998; 91:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/3\">",
"      Yamaguchi M, Sayama K, Yano K, et al. IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J Immunol 1999; 162:5455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/4\">",
"      Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108:E36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/5\">",
"      Kinet JP. The gamma-zeta dimers of Fc receptors as connectors to signal transduction. Curr Opin Immunol 1992; 4:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/6\">",
"      Cambier JC. Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). J Immunol 1995; 155:3281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/7\">",
"      Ishizaka K, Tomioka H, Ishizaka T. Mechanisms of passive sensitization. I. Presence of IgE and IgG molecules on human leukocytes. J Immunol 1970; 105:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/8\">",
"      Kinet JP. The high-affinity receptor for IgE. Curr Opin Immunol 1989- 1990; 2:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/9\">",
"      Bieber T, de la Salle H, Wollenberg A, et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J Exp Med 1992; 175:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/10\">",
"      Schwartz LB. Effector cells of anaphylaxis: mast cells and basophils. Novartis Found Symp 2004; 257:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/11\">",
"      Grayson MH, Cheung D, Rohlfing MM, et al. Induction of high-affinity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia. J Exp Med 2007; 204:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/12\">",
"      Guo CB, Kagey-Sobotka A, Lichtenstein LM, Bochner BS. Immunophenotyping and functional analysis of purified human uterine mast cells. Blood 1992; 79:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/13\">",
"      Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: Up-regulation by IFN-gamma. J Immunol 2000; 164:4332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/14\">",
"      Woolhiser MR, Okayama Y, Gilfillan AM, Metcalfe DD. IgG-dependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma. Eur J Immunol 2001; 31:3298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/15\">",
"      Meininger CJ, Yano H, Rottapel R, et al. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 1992; 79:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/16\">",
"      Murakami M, Austen KF, Arm JP. The immediate phase of c-kit ligand stimulation of mouse bone marrow-derived mast cells elicits rapid leukotriene C4 generation through posttranslational activation of cytosolic phospholipase A2 and 5-lipoxygenase. J Exp Med 1995; 182:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/17\">",
"      Murakami M, Matsumoto R, Austen KF, Arm JP. Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J Biol Chem 1994; 269:22269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/18\">",
"      Lu-Kuo JM, Austen KF, Katz HR. Post-transcriptional stabilization by interleukin-1beta of interleukin-6 mRNA induced by c-kit ligand and interleukin-10 in mouse bone marrow-derived mast cells. J Biol Chem 1996; 271:22169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/19\">",
"      Bischoff SC, Dahinden CA. c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med 1992; 175:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/20\">",
"      Costa JJ, Demetri GD, Harrist TJ, et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996; 183:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/21\">",
"      Feldweg AM, Friend DS, Zhou JS, et al. gp49B1 suppresses stem cell factor-induced mast cell activation-secretion and attendant inflammation in vivo. Eur J Immunol 2003; 33:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/22\">",
"      F&uuml;reder W, Agis H, Willheim M, et al. Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol 1995; 155:3152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/23\">",
"      el-Lati SG, Dahinden CA, Church MK. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol 1994; 102:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/24\">",
"      Nilsson G, Johnell M, Hammer CH, et al. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 1996; 157:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/25\">",
"      Schulman ES, Post TJ, Henson PM, Giclas PC. Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest 1988; 81:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/26\">",
"      McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol 2003; 170:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/27\">",
"      Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol 2004; 114:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/28\">",
"      Varadaradjalou S, F&eacute;ger F, Thieblemont N, et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol 2003; 33:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/29\">",
"      Marshall JS, Jawdat DM. Mast cells in innate immunity. J Allergy Clin Immunol 2004; 114:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/30\">",
"      Marshall JS, McCurdy JD, Olynych T. Toll-like receptor-mediated activation of mast cells: implications for allergic disease? Int Arch Allergy Immunol 2003; 132:87.",
"     </a>",
"    </li>",
"    <li>",
"     Church MK, et al. Functional heterogeneity of human mast cells. In: Mast cell and basophil differentiation and function in health and disease, Galli SJ, Austen KF (Eds), Raven Press, Raven Press 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/32\">",
"      Benyon RC, Lowman MA, Church MK. Human skin mast cells: their dispersion, purification, and secretory characterization. J Immunol 1987; 138:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/33\">",
"      Church MK, el-Lati S, Caulfield JP. Neuropeptide-induced secretion from human skin mast cells. Int Arch Allergy Appl Immunol 1991; 94:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/34\">",
"      Aridor M, Traub LM, Sagi-Eisenberg R. Exocytosis in mast cells by basic secretagogues: evidence for direct activation of GTP-binding proteins. J Cell Biol 1990; 111:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/35\">",
"      Mousli M, Bronner C, Bueb JL, Landry Y. Evidence for the interaction of mast cell-degranulating peptide with pertussis toxin-sensitive G proteins in mast cells. Eur J Pharmacol 1991; 207:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/36\">",
"      Tatemoto K, Nozaki Y, Tsuda R, et al. Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. Biochem Biophys Res Commun 2006; 349:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/37\">",
"      Wang LL, Mehta IK, LeBlanc PA, Yokoyama WM. Mouse natural killer cells express gp49B1, a structural homologue of human killer inhibitory receptors. J Immunol 1997; 158:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/38\">",
"      Stellato C, de Paulis A, Cirillo R, et al. Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 1991; 74:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/39\">",
"      Moss J, Rosow CE. Histamine release by narcotics and muscle relaxants in humans. Anesthesiology 1983; 59:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/40\">",
"      Kajiwara N, Sasaki T, Bradding P, et al. Activation of human mast cells through the platelet-activating factor receptor. J Allergy Clin Immunol 2010; 125:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/41\">",
"      Katz HR. Inhibitory receptors and allergy. Curr Opin Immunol 2002; 14:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/42\">",
"      Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007; 120:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/43\">",
"      Yokoi H, Myers A, Matsumoto K, et al. Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells. Allergy 2006; 61:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/44\">",
"      Da&euml;ron M, Malbec O, Latour S, et al. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995; 95:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/45\">",
"      Daheshia M, Friend DS, Grusby MJ, et al. Increased severity of local and systemic anaphylactic reactions in gp49B1-deficient mice. J Exp Med 2001; 194:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/46\">",
"      Zhou JS, Friend DS, Lee DM, et al. gp49B1 deficiency is associated with increases in cytokine and chemokine production and severity of proliferative synovitis induced by anti-type II collagen mAb. Eur J Immunol 2005; 35:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/47\">",
"      Voehringer D, Rosen DB, Lanier LL, Locksley RM. CD200 receptor family members represent novel DAP12-associated activating receptors on basophils and mast cells. J Biol Chem 2004; 279:54117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/48\">",
"      Cherwinski HM, Murphy CA, Joyce BL, et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol 2005; 174:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/49\">",
"      Zhang S, Phillips JH. Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation. J Leukoc Biol 2006; 79:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/50\">",
"      Kojima T, Obata K, Mukai K, et al. Mast cells and basophils are selectively activated in vitro and in vivo through CD200R3 in an IgE-independent manner. J Immunol 2007; 179:7093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/51\">",
"      Bachelet I, Munitz A, Moretta A, et al. The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J Immunol 2005; 175:7989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/52\">",
"      Okoshi Y, Tahara-Hanaoka S, Nakahashi C, et al. Requirement of the tyrosines at residues 258 and 270 of MAIR-I in inhibitory effect on degranulation from basophilic leukemia RBL-2H3. Int Immunol 2005; 17:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/53\">",
"      Simhadri VR, Andersen JF, Calvo E, et al. Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. Blood 2012; 119:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/54\">",
"      Nakahashi-Oda C, Tahara-Hanaoka S, Shoji M, et al. Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor. J Exp Med 2012; 209:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/55\">",
"      Chong LK, Morice AH, Yeo WW, et al. Functional desensitization of beta agonist responses in human lung mast cells. Am J Respir Cell Mol Biol 1995; 13:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/56\">",
"      Church MK, Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol 1987; 90:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/57\">",
"      Okayama Y, Church MK. Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. Int Arch Allergy Immunol 1992; 97:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/58\">",
"      Zhu D, Kepley CL, Zhang K, et al. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005; 11:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/59\">",
"      Mertsching E, Bafetti L, Hess H, et al. A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases. J Allergy Clin Immunol 2008; 121:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/60\">",
"      Goodridge HS, Marshall FA, Else KJ, et al. Immunomodulation via novel use of TLR4 by the filarial nematode phosphorylcholine-containing secreted product, ES-62. J Immunol 2005; 174:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/61\">",
"      Melendez AJ, Harnett MM, Pushparaj PN, et al. Inhibition of Fc epsilon RI-mediated mast cell responses by ES-62, a product of parasitic filarial nematodes. Nat Med 2007; 13:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/62\">",
"      Jouvin MH, Adamczewski M, Numerof R, et al. Differential control of the tyrosine kinases Lyn and Syk by the two signaling chains of the high affinity immunoglobulin E receptor. J Biol Chem 1994; 269:5918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/63\">",
"      Yamashita T, Mao SY, Metzger H. Aggregation of the high-affinity IgE receptor and enhanced activity of p53/56lyn protein-tyrosine kinase. Proc Natl Acad Sci U S A 1994; 91:11251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/64\">",
"      Wilson BS, Kapp N, Lee RJ, et al. Distinct functions of the Fc epsilon R1 gamma and beta subunits in the control of Fc epsilon R1-mediated tyrosine kinase activation and signaling responses in RBL-2H3 mast cells. J Biol Chem 1995; 270:4013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/65\">",
"      Oliver JM, Burg DL, Wilson BS, et al. Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J Biol Chem 1994; 269:29697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/66\">",
"      Kambayashi T, Koretzky GA. Proximal signaling events in Fc epsilon RI-mediated mast cell activation. J Allergy Clin Immunol 2007; 119:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/67\">",
"      Blumer KJ, Johnson GL. Diversity in function and regulation of MAP kinase pathways. Trends Biochem Sci 1994; 19:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/68\">",
"      Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 1995; 20:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/69\">",
"      Hirasawa N, Santini F, Beaven MA. Activation of the mitogen-activated protein kinase/cytosolic phospholipase A2 pathway in a rat mast cell line. Indications of different pathways for release of arachidonic acid and secretory granules. J Immunol 1995; 154:5391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/70\">",
"      Hirasawa N, Scharenberg A, Yamamura H, et al. A requirement for Syk in the activation of the microtubule-associated protein kinase/phospholipase A2 pathway by Fc epsilon R1 is not shared by a G protein-coupled receptor. J Biol Chem 1995; 270:10960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/71\">",
"      Glover S, de Carvalho MS, Bayburt T, et al. Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. J Biol Chem 1995; 270:15359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/72\">",
"      Divecha N, Irvine RF. Phospholipid signaling. Cell 1995; 80:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/73\">",
"      Fukamachi H, Kawakami Y, Takei M, et al. Association of protein-tyrosine kinase with phospholipase C-gamma 1 in bone marrow-derived mouse mast cells. Proc Natl Acad Sci U S A 1992; 89:9524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/74\">",
"      Lewin I, Jacob-Hirsch J, Zang ZC, et al. Aggregation of the Fc epsilon RI in mast cells induces the synthesis of Fos-interacting protein and increases its DNA binding-activity: the dependence on protein kinase C-beta. J Biol Chem 1996; 271:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/75\">",
"      Razin E, Szallasi Z, Kazanietz MG, et al. Protein kinases C-beta and C-epsilon link the mast cell high-affinity receptor for IgE to the expression of c-fos and c-jun. Proc Natl Acad Sci U S A 1994; 91:7722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/76\">",
"      Marquardt DL, Alongi JL, Walker LL. The phosphatidylinositol 3-kinase inhibitor wortmannin blocks mast cell exocytosis but not IL-6 production. J Immunol 1996; 156:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/77\">",
"      Fruman DA, Bierer BE, Benes JE, et al. The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. J Immunol 1995; 154:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/78\">",
"      Penner R, Matthews G, Neher E. Regulation of calcium influx by second messengers in rat mast cells. Nature 1988; 334:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/79\">",
"      Erb KJ. Can helminths or helminth-derived products be used in humans to prevent or treat allergic diseases? Trends Immunol 2009; 30:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/80\">",
"      Harnett MM, Melendez AJ, Harnett W. The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease. Clin Exp Immunol 2010; 159:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20936/abstract/81\">",
"      Zhang K, Zhu D, Kepley C, et al. Chimeric human fcgamma-allergen fusion proteins in the prevention of allergy. Immunol Allergy Clin North Am 2007; 27:93.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3981 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20936=[""].join("\n");
var outline_f20_28_20936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACTIVATING RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      High affinity IgE receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IgG receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Stem cell factor receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Complement receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Toll-like receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Receptors for neuropeptides and opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Platelet activating factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INHIBITORY RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Leukocyte immunoglobulin-like receptor 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CD200 receptor 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H627444214\">",
"      CD300a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Beta adrenoreceptor 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      IgG receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Toll-like receptor 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SIGNAL TRANSDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H174337300\">",
"      CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=related_link\">",
"      Mast cell derived mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=related_link\">",
"      Mast cells: Development, identification, and physiologic roles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30889?source=related_link\">",
"      NK cell deficiency syndromes: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18778?source=related_link\">",
"      Pathophysiology of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=related_link\">",
"      Treatment and prognosis of systemic mastocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_28_20937="Mast cell activation disorders";
var content_f20_28_20937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mast cell activation disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20937/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20937/contributors\">",
"     Cem Akin, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20937/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20937/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20937/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20937/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/28/20937/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5001792\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mast cell activation disorders present with recurrent symptoms of mast cell activation, in combination with objective evidence of mast cell mediator release. Two mast cell activation disorders have been recently proposed and defined:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monoclonal mast cell activation syndrome (MMAS)",
"     </li>",
"     <li>",
"      Mast cell activation syndrome (MCAS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the classification of mast cell disorders and then focus on MMAS and MCAS, describing the clinical manifestations, evaluation, diagnosis, and treatment of these disorders. By the time a mast cell disorder is considered, patients have typically undergone evaluation for a wide array of disorders, both allergic and nonallergic. Disorders that can mimic allergic reactions and anaphylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38888?source=see_link\">",
"     \"Differential diagnosis of anaphylaxis in children and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25846270\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF MAST CELL DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cell disorders can be broadly divided into three types: primary, secondary, and idiopathic (",
"    <a class=\"graphic graphic_table graphicRef74166 \" href=\"UTD.htm?39/31/40443\">",
"     table 1",
"    </a>",
"    ). All of these disorders present with signs and symptoms of mast cell activation and differ in severity and involvement of various organ systems. Within this framework, MMAS is best classified as a primary mast cell disorder, while MCAS is considered an idiopathic disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25846317\">",
"    <span class=\"h2\">",
"     Primary mast cell disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary disorders of mast cells are associated with intrinsic defects in mast cells affecting proliferation or activation pathways. In these disorders, clonal populations of mast cells arise from an affected progenitor and display abnormal genetic and surface markers. Stem cell factor (SCF) is critical for mast cell growth and differentiation from hematopoietic progenitors, as well as their survival and chemotaxis. The transmembrane receptor for SCF is KIT (encoded by the protooncogene c-kit). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=see_link&amp;anchor=H5#H5\">",
"     \"Mast cells: Surface receptors and signal transduction\", section on 'Stem cell factor receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25846324\">",
"    <span class=\"h3\">",
"     Mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best characterized primary mast cell disorder is mastocytosis. Systemic and cutaneous forms of the disease are well described. Patients with systemic mastocytosis (SM) experience episodes of symptoms caused by mast cell mediator release, which last a few minutes to several hours. Common signs and symptoms include flushing, gastrointestinal cramping, and hypotension. Some patients present with hypotensive reactions to Hymenoptera stings, even in the absence of detectable venom-specific IgE. In addition, 80 percent of patients with SM demonstrate a characteristic skin finding, called urticaria pigmentosa (",
"    <a class=\"graphic graphic_picture graphicRef63025 \" href=\"UTD.htm?40/49/41746\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An elevation in serum total tryptase in a patient who is in their normal state (ie, not during or within hours of an episode of symptoms) is strongly suggestive of systemic mastocytosis. Normal levels are between 1 and 11.4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (some laboratories consider 15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    to be the upper limit of normal) (",
"    <a class=\"graphic graphic_table graphicRef74223 \" href=\"UTD.htm?33/15/34044\">",
"     table 2",
"    </a>",
"    ). Patients with systemic mastocytosis typically demonstrate total serum tryptase &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Other causes of an elevated baseline serum tryptase are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=see_link&amp;anchor=H14#H14\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\", section on 'Elevations of tryptase in nonanaphylactic patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More than 90 percent of adult patients with systemic mastocytosis have a point mutation (D816V) in exon 17 of the c-kit gene. This mutation is the only well-characterized molecular defect associated with both increased mast cell numbers in tissues (systemic mastocytosis)",
"    <strong>",
"     and",
"    </strong>",
"    clinical signs and symptoms of mast cell activation. Systemic mastocytosis is diagnosed according to major and minor criteria, which are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link&amp;anchor=H25#H25\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25846331\">",
"    <span class=\"h3\">",
"     Monoclonal mast cell activation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal mast cell activation syndrome (MMAS) was recognized as a distinct primary mast cell disorder by an international consensus conference in 2007 (",
"    <a class=\"graphic graphic_table graphicRef74223 \" href=\"UTD.htm?33/15/34044\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with MMAS have recurrent episodes of mast cell activation symptoms such as recurrent flushing, gastrointestinal cramping, and hypotension, similar to patients with systemic mastocytosis. They may present with hypotensive reactions to Hymenoptera stings, similar to patients with mastocytosis. However, they lack urticaria pigmentosa and demonstrate baseline serum tryptase values that are normal or mildly increased [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Some of these patients may have been formerly diagnosed as having idiopathic anaphylaxis or exercise-induced anaphylaxis. (See",
"    <a class=\"local\" href=\"#H4038466\">",
"     'Idiopathic anaphylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with MMAS have a clonal population of mast cells, as demonstrated by c-KIT point mutations (most commonly D816V) and aberrant CD25 (alpha chain of the high affinity IL-2 receptor) expression on bone marrow analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/6\">",
"     6",
"    </a>",
"    ]. However, these findings may be only detectable in a bone marrow sample enriched for mast cells rather than in unfractionated bone marrow, or when sensitive diagnostic assays (such as those based on mutation specific primers) are employed. Thus, patients with MMAS display one or two minor criteria (namely, c-KIT mutation or CD25 expression) for systemic mastocytosis but do not fully meet requirements for that diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25846339\">",
"    <span class=\"h2\">",
"     Secondary mast cell activation disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary mast cell activation disorders are conditions in which mast cells are normal in quantity and function and are responding to an external stimulus such as allergen, autoantibody, drug, or products of complement activation (",
"    <a class=\"graphic graphic_table graphicRef57791 \" href=\"UTD.htm?13/46/14059\">",
"     table 3",
"    </a>",
"    ). Disorders in this category include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic diseases &mdash; IgE-mediated allergies to foods, drugs, and a variety of other allergens.",
"     </li>",
"     <li>",
"      Some types of physical urticaria and chronic urticaria.",
"     </li>",
"     <li>",
"      Neoplastic and hematologic disorders &mdash; Secondary increases in mast cell numbers infiltrating affected tissues can be seen in occasional patients with solid tumors, such as breast cancer, Hodgkin lymphoma, skin and connective tissue tumors, and in diseases variably associated with increased expression of stem cell factor, such as aplastic anemia. Reactive mast cells generally have a mature appearance (round in shape and fully granulated) and lack the surface marker abnormalities found in primary mast cell disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25846346\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term idiopathic is assigned when no identifiable cause of mast cell activation can be identified. In addition to mast cell activation syndrome (MCAS), idiopathic chronic urticaria, idiopathic angioedema, and idiopathic anaphylaxis are included in this category.",
"   </p>",
"   <p>",
"    It is possible that disorders that are now classified as idiopathic may ultimately be shown to be primary mast cell disorders in the future if new genetic defects are identified. Alternatively, these disorders may prove to be secondary mast cell disorders for which an exogenous stimulus exists but has not been identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=see_link\">",
"     \"Idiopathic anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25846353\">",
"    <span class=\"h3\">",
"     Mast cell activation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The existence of an additional idiopathic disorder of mast cell hyperreactivity, called mast cell activation syndrome (MCAS), was adopted by an international working group in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The clinical presentation involves episodes of symptoms due to mast cell mediator release,",
"    <strong>",
"     without",
"    </strong>",
"    evidence of a pathologic increase in mast cell numbers in the tissues. Patients should have biochemical evidence of mast cell activation during a symptomatic period.",
"   </p>",
"   <p>",
"    Patients with MCAS lack urticaria pigmentosa, similar to those with monoclonal mast cell activation syndrome (MMAS). Provisional diagnostic criteria for this disorder have been defined and are discussed below (",
"    <a class=\"graphic graphic_table graphicRef74223 \" href=\"UTD.htm?33/15/34044\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4038188\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It has been suggested that MCAS be assigned to patients whose symptoms do",
"    <strong>",
"     not",
"    </strong>",
"    meet the clinical definition of anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"UTD.htm?22/43/23228\">",
"     table 4",
"    </a>",
"    ), to distinguish MCAS from idiopathic anaphylaxis. If episodes do meet criteria for anaphylaxis, then the diagnosis of idiopathic anaphylaxis is more appropriate. Therefore, at the time of this review, MCAS is appropriately diagnosed",
"    <strong>",
"     only",
"    </strong>",
"    when other primary and secondary disorders of mast cell have been excluded and the patient&rsquo;s symptoms do not",
"    <strong>",
"    </strong>",
"    fulfill the diagnosis of anaphylaxis. (See",
"    <a class=\"local\" href=\"#H4038466\">",
"     'Idiopathic anaphylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4290513\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS OF MAST CELL ACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of mast cell disorders are caused by the episodic release of vasoactive and inflammatory mediators from mast cells. There is no single symptom that is specific to mast cell activation. Rather, patients with mast cell disorders typically present with some combination of the signs and symptoms described in this section.",
"   </p>",
"   <p>",
"    Some patients present with recurrent episodes of anaphylaxis, while others have experienced less severe symptoms resembling allergic reactions, for which no consistent trigger or cause has been identified. Symptoms generally occur episodically, lasting minutes to a few hours. It should be noted that while some patients may have some symptoms outside of the acute episodes, chronic symptoms experienced on a daily basis are not typical of mast cell activation events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1091266\">",
"    <span class=\"h2\">",
"     Provoking exposures and activities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The release of mast cell mediators in patients with mast cell disorders may be precipitated by a variety of stimuli, although not all triggers cause symptoms in every patient. Potential provoking factors include the following (",
"    <a class=\"graphic graphic_table graphicRef70309 \" href=\"UTD.htm?40/37/41563\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/3,9-11\">",
"     3,9-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Medications",
"      </strong>",
"      : Narcotics, opioids, NSAIDs, iodinated contrast agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      , and neuromuscular blocking agents used in anesthesia can each trigger episodes of symptoms. In evaluating medications as potential triggers, pharmacologic adverse effects of the medications or intolerances should be differentiated from symptoms caused by mast cell activation. For example, gastrointestinal intolerance is a common adverse effect of NSAIDs and is usually not related to mast cell activation. The time frame of the reaction should also be consistent with an immediate mast cell-mediated event. For example, delayed-onset maculopapular rashes often occur through a non mast cell-mediated mechanism and should not raise suspicion for a mast cell disorder.",
"     </li>",
"     <li>",
"      <strong>",
"       Physical factors",
"      </strong>",
"      : Physical stimuli, such as exercise, massage or friction applied to the skin, extremes of temperature, sudden temperature changes, and very spicy foods can elicit symptoms.",
"     </li>",
"     <li>",
"      <strong>",
"       Surgical procedures or instrumentation (including biopsies or endoscopy)",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Alcohol ingestion",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <strong>",
"       Infections (including viral, bacterial, and parasitic) and fever",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Emotional stress",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Toxic exposures",
"      </strong>",
"      : Including stings of jellyfish, snake bites, etc.",
"     </li>",
"     <li>",
"      <strong>",
"       Hymenoptera stings",
"      </strong>",
"      : Stings of bees, wasps, yellow jackets, hornets, and imported fire ants can elicit symptoms, either through nonallergic or IgE-mediated allergic mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/3,4,13\">",
"       3,4,13",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link&amp;anchor=H24#H24\">",
"       \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\", section on 'Concomitant allergic disease'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4038003\">",
"    <span class=\"h2\">",
"     Specific organ systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The organ systems involved are the skin and soft tissues (mucosae), upper and lower respiratory tract, cardiovascular system, gastrointestinal tract, and musculoskeletal system. Some patients experience neuropsychiatric symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4290520\">",
"    <span class=\"h3\">",
"     Skin and soft tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients often experience flushing, caused by vasodilatory effects of histamine and lipid derived mast cell mediators. Flushing may be induced by exercise, alcohol, temperature changes, and emotional events. In our experience, patients with mast cell disorders develop flushing in association with signs and symptoms in other organ systems, whereas flushing in isolation is an uncommon presentation and may be due to other causes, such as autonomic dysfunction. Patients may also present with pruritus, urticaria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema, although these symptoms are less frequent in primary mast cell disorders (such as mastocytosis) and are more characteristic of secondary (such as IgE-mediated allergic disease) or idiopathic mast cell activation disorders. (See",
"    <a class=\"local\" href=\"#H25846270\">",
"     'Classification of mast cell disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The differential diagnosis of flushing is extensive and includes hormonal, neurologic, and cardiovascular etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/14\">",
"     14",
"    </a>",
"    ]. The flushing observed in mast cell disorders is of longer duration, lasting minutes to a few hours, and usually is not accompanied by sweating, whereas perimenopausal hot flashes usually last two to four minutes and are often accompanied by sweating. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12857?source=see_link\">",
"     \"Approach to flushing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1091826\">",
"    <span class=\"h4\">",
"     Urticaria pigmentosa and other cutaneous lesions of mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria pigmentosa (UP) is a skin lesion characterized by small fixed yellow-tan to reddish&ndash;brown macules or slightly raised papules (",
"    <a class=\"graphic graphic_picture graphicRef63025 \" href=\"UTD.htm?40/49/41746\">",
"     picture 1",
"    </a>",
"    ). Urticaria pigmentosa or other forms of cutaneous mastocytosis are NOT seen in patients with secondary or idiopathic mast cell activation disorders, so UP is an important diagnostic clue that another type of mast cell disorder is present. UP is found in children and adults with cutaneous or systemic mastocytosis, disorders that are reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\", section on 'Skin findings and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4290527\">",
"    <span class=\"h3\">",
"     Respiratory and naso-ocular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cell activation can result in upper and lower airway symptoms, including rhinorrhea, conjunctival injection and ocular itching, and bronchoconstriction resulting in shortness of breath and wheezing. In contrast, angioedema of the mucosal linings in the upper airways (eg, laryngeal edema) is relatively uncommon in primary mast cell disorders and is more characteristic of secondary (eg, allergic) or idiopathic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4290534\">",
"    <span class=\"h3\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic mast cell degranulation can lead to episodic hypotension with resultant lightheadedness and syncope. A compensatory tachycardia is typically associated with the hypotensive event; although other rhythm abnormalities and life threatening myocardial perfusion abnormalities can be superimposed, especially in patients with coexisting structural heart disease. Mast cell disease is thus included in the differential diagnosis of patients with unexplained recurrent syncopal episodes, especially those associated with other symptoms, such as flushing and gastrointestinal complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4290541\">",
"    <span class=\"h3\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic mast cell degranulation is frequently associated with gastrointestinal complaints, such as pain, heartburn, nausea, vomiting, diarrhea, and abdominal cramping [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. Heartburn and nausea may be partially caused by gastric acid hypersecretion from parietal cells, which can be stimulated by histamine in patients with increased mast cell burden. However, the physiologic basis of diarrhea and abdominal pain in mast cell disorders is largely unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4290548\">",
"    <span class=\"h3\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mast cell disorders often complain about generalized aches and pains resembling fibromyalgia, although inflammatory joint swelling and effusion are rarely encountered. The mechanism by which mast cells contribute to these symptoms is not well described, although mast cells have been found to be increased in synovial tissue in rheumatoid arthritis and mast cell derived tumor necrosis factor (TNF)-alpha has been implicated to play an important role in cartilage destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4290562\">",
"    <span class=\"h3\">",
"     Neuropsychiatric",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache, fatigue, lack of concentration, and mild cognitive problems are frequent complaints in patients with mast cell disorders, as well as those with allergic disorders. These symptoms may be due to the effects of mast cell mediators, medications or psychosomatic effects of having a chronic illness. Neuropsychiatric symptoms should be accompanied by signs and symptoms involving at least two other organ systems if they are to be considered mast cell-related.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3576996\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH AND ALGORITHM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of patients with suspected mast cell disorders involves a detailed clinical history, physical examination to exclude signs or findings of other disorders, and laboratory studies (",
"    <a class=\"graphic graphic_algorithm graphicRef52981 \" href=\"UTD.htm?24/44/25280\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5002256\">",
"    <span class=\"h2\">",
"     Indications for evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evaluation for mast cell disorders should be considered in a patient with manifestations of mast cell activation, such as flushing, urticaria, diarrhea, abdominal cramping, wheezing, syncope, or near syncope, affecting",
"    <strong>",
"     at least two",
"    </strong>",
"    organ systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H655017\">",
"    <span class=\"h2\">",
"     When to refer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with signs and symptoms of a mast cell activation disorder should be referred to an",
"    <span class=\"nowrap\">",
"     allergy/immunology",
"    </span>",
"    or hematology expert with knowledge about these disorders, when possible. Measurement of tryptase in the serum, histamine in plasma, or other mast cell mediators in a 24 hour urine specimen (N-Methylhistamine, PGD2 or 11- &beta; PGF2), at baseline and following an episode of symptoms, is critical to the diagnosis and can be obtained by the generalist in advance of referral. Proper collection of samples for measurement of mast cell mediators is described below. (See",
"    <a class=\"local\" href=\"#H5002284\">",
"     'Document mast cell mediator release'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5002263\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each episode of symptoms that the patient can describe should be reviewed in detail to determine if the signs and symptoms are consistent with mast cell activation. In addition, the clinician should attempt to discern triggering factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5002270\">",
"    <span class=\"h2\">",
"     Determine if urticaria pigmentosa is present",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful skin examination should be performed to determine if urticaria pigmentosa (UP) skin lesions are present (",
"    <a class=\"graphic graphic_picture graphicRef63025 \" href=\"UTD.htm?40/49/41746\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H1091826\">",
"     'Urticaria pigmentosa and other cutaneous lesions of mastocytosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If UP is present, the patient should undergo an evaluation for systemic and cutaneous mastocytosis, including a bone marrow biopsy in adults. UP is found in 80 percent of adult patients with systemic mastocytosis and also constitutes a physical finding of cutaneous mastocytosis. Bone marrow evaluation is described in greater detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"       \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If UP is not present, the patient may still have a mast cell activation disorder (ie, MMAS or MCAS) and the evaluation should continue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1092166\">",
"    <span class=\"h2\">",
"     Determine baseline serum tryptase and need for bone marrow biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum tryptase is the most specific marker of mast cell activation currently available. An assay for total tryptase is available as \"ImmunoCAP tryptase\" (Phadia: Uppsala, Sweden), and can be obtained through many commercial labs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/18\">",
"     18",
"    </a>",
"    ]. Values &gt;11.4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    are considered elevated in most diagnostic laboratories. A relative increase in serum total tryptase is also indicative of mast cell activation. Increases greater than 1.2 X baseline value + 2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    are considered significant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/8\">",
"     8",
"    </a>",
"    ]. For example, if a patient&rsquo;s baseline total tryptase were 5",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    a value of 8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    would represent a significant increase.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum tryptase level is &gt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      when the patient is in a baseline state, an evaluation for systemic mastocytosis should be performed, since this degree of elevation is a minor diagnostic criterion for systemic mastocytosis (",
"      <a class=\"graphic graphic_table graphicRef82827 \" href=\"UTD.htm?10/20/10572\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/19\">",
"       19",
"      </a>",
"      ]. Other disorders in which baseline tryptase can be persistently elevated include other hematologic disorders, such as chronic eosinophilic leukemia, myelodysplastic syndromes, acute leukemias, chronic renal insufficiency, and bone marrow suppression states. These disorders can generally be diagnosed based on peripheral blood and bone marrow findings and renal function tests. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"       \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the serum tryptase is &lt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      when the patient is in a baseline state, then a bone marrow biopsy is less likely to reveal the characteristic multifocal bone marrow aggregates of spindle-shaped mast cells in the bone marrow, which is the major diagnostic criterion for systemic mastocytosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If a patient with a serum tryptase &lt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      had documented hypotension or syncope during episodes of symptoms, especially in the absence of urticaria and angioedema, then we still proceed with a bone marrow evaluation, because",
"      <span class=\"nowrap\">",
"       hypotension/syncope",
"      </span>",
"      is characteristic of patients with mastocytosis and MMAS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/20\">",
"       20",
"      </a>",
"      ]. Alternatively, the clinician could consider referral to a mast cell disease research center [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/21\">",
"       21",
"      </a>",
"      ]. At these centers, bone marrow samples can also be analyzed using specialized techniques (such as mast cell flow cytometry [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/22\">",
"       22",
"      </a>",
"      ] and mutational analysis of the mast cell enriched bone marrow samples [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/23\">",
"       23",
"      </a>",
"      ]), which have been developed to demonstrate small populations of abnormal mast cell populations. These techniques may not be routinely available in many diagnostic hematopathology laboratories.",
"     </li>",
"     <li>",
"      If a patient with a serum tryptase &lt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      does not have documented hypotension or syncope or has urticaria and angioedema as a prominent feature of the episodes, bone marrow studies are less likely to reveal a diagnostic abnormality for a primary mast cell disorder but may be considered on a case by case basis. For example, a bone marrow biopsy in patients with chronic urticaria or recurrent angioedema is generally not pursued unless there is another indication.",
"     </li>",
"     <li>",
"      If a patient has a serum total tryptase &lt;20",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      but has significant increases in total tryptase following symptoms, then a bone marrow biopsy may also be considered on an individual case basis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5299554\">",
"    <span class=\"h3\">",
"     Bone marrow findings in MMAS and MCAS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with MMAS, mast cells often display aberrant morphology, such as spindling and hypogranulation and are positive for CD25. Bone marrow mast cells may show a tropism for blood vessels and bone trabeculae and form small clusters that do not reach the threshold for systemic mastocytosis (ie, clusters of at least 15 mast cells each).",
"     </li>",
"     <li>",
"      In patients with MCAS, there may be subtle abnormalities in mast cell morphology in bone marrow examination, such as spindling and small clustering of two or three cells. However, large clusters typical of systemic mastocytosis are absent and clonal markers, such as c-kit mutation or mast cell CD25 expression are also lacking.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15529537\">",
"    <span class=\"h3\">",
"     The utility of other tissue biopsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow is the preferred tissue to biopsy when evaluating patients for systemic mast cell disorders. Biopsies of other tissues are generally not helpful in this setting, because the finding of increased numbers of mast cells in other tissues is relatively nonspecific. For example, increased mast cells in gastrointestinal biopsies are also seen in patients with eosinophilic esophagitis and bacterial and parasitic infections. Occasionally, it may be possible to diagnose mastocytosis through a colonic biopsy in a patient with recurrent diarrhea if the mast cells occur in clusters and express CD25 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a patient is referred to our clinic with the potential diagnosis of a systemic mast cell disorder (either systemic mastocytosis or a mast cell activation disorder) based on increased numbers of mast cells in gastrointestinal tract or skin biopsies, we attempt to verify or exclude systemic mastocytosis according to WHO criteria, which involves staining of the biopsies for CD25 as well as bone marrow biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5002277\">",
"    <span class=\"h2\">",
"     Exclude allergic disease or other causes of secondary mast cell activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any defined allergic disorders that could explain all or part of the patient&rsquo;s presentation should be considered, if not already done. These include chronic",
"    <span class=\"nowrap\">",
"     urticaria/angioedema,",
"    </span>",
"    allergies to foods or food additives, drugs, environmental allergens, physical factors (exercise-induced anaphylaxis, cold urticaria, cholinergic urticaria, and delayed pressure urticaria), allergic asthma, or other defined disorders. It should be noted that patients with IgE-mediated hymenoptera venom anaphylaxis may still have a coexisting clonal mast cell disorder, especially if they have an elevated baseline tryptase level or experience hypotensive anaphylaxis after the sting. For patients presenting with anaphylaxis, an approach to determining an underlying etiology is outlined separately. If no etiology is found, the diagnosis of idiopathic anaphylaxis should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9401?source=see_link&amp;anchor=H4433858#H4433858\">",
"     \"Anaphylaxis: Confirming the diagnosis and determining the trigger(s)\", section on 'Testing for allergen trigger(s)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=see_link\">",
"     \"Idiopathic anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5002284\">",
"    <span class=\"h2\">",
"     Document mast cell mediator release",
"    </span>",
"    &nbsp;&mdash;&nbsp;Documentation of mast cell mediator release during and in the hours immediately after episodes of symptoms is critical in determining if the patient&rsquo;s symptoms are due to mast cell activation. These tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum tryptase (which should be obtained between 0.5 and 4 hours after the onset of symptoms): This is the most specific marker of mast cell activation and assays for serum tryptase are widely available. A detailed discussion about the interpretation of serum tryptase levels is provided separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=see_link&amp;anchor=H4#H4\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\", section on 'Tryptase'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      N-methylhistamine, measured in a 24 hour urine specimen: Collection of urine should begin as soon as possible after the onset of symptoms. This test is available through commercial laboratories [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/25\">",
"       25",
"      </a>",
"      ]. Urine histamine is less specific as it can be influenced by dietary changes and urinary tract flora.",
"     </li>",
"     <li>",
"      Prostaglandin D2 or its metabolite, 11&beta; prostaglandin F2 alpha, measured in a 24 hour urine specimen: Patients taking NSAIDs for any reason should discontinue these if feasible from clinical standpoint prior to collection of urine, because NSAIDs block PGD2 synthesis. These tests are available through commercial laboratories [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Plasma histamine: Elevations of plasma histamine correlate well with clinical severity of anaphylaxis. Although histamine levels in properly collected samples of plasma have a greater sensitivity than tryptase, the short plasma half-life of histamine and the difficulties in handling the sample usually limit the utility of this measurement in the clinical setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=see_link&amp;anchor=H17#H17\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\", section on 'Histamine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Levels of these mediators during symptomatic periods should be compared with patient's baseline values. Transient increases are consistent with episodes of mast cell activation and provide evidence that mast cells are responsible for the patient&rsquo;s symptoms.",
"   </p>",
"   <p>",
"    Some patients do not fulfill the clinical criteria for anaphylaxis, elevations in mast cell mediators are",
"    <strong>",
"     not",
"    </strong>",
"    detected immediately following symptoms, and the workup fails to identify a diagnosis. In such patients, there is no objective biochemical evidence for a mast cell disorder and the differential diagnosis of mast cell activation and anaphylaxis should be revisited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38888?source=see_link\">",
"     \"Differential diagnosis of anaphylaxis in children and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1092311\">",
"    <span class=\"h2\">",
"     Assess response to anti-mediator treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If transient elevations in mast cell mediators can be demonstrated, and no secondary cause of mast cell activation is found, then the patient should be treated with one or more therapies to counteract the various mediators released from mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/12\">",
"     12",
"    </a>",
"    ]. Improvement of symptoms with drugs that target mast cell mediators provides further supporting evidence of mast cell involvement in disease process and is one of the proposed diagnostic criteria for a mast cell activation disorder (",
"    <a class=\"graphic graphic_table graphicRef74223 \" href=\"UTD.htm?33/15/34044\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Therapies are chosen based upon the patient&rsquo;s symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H1 antihistamines are appropriate for patients with pruritus, urticaria, or anaphylaxis. Commonly used H1 antihistamines (adult dosing) include oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      (10 mg daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      (180 mg daily), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      (25 mg every six hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/26\">",
"       26",
"      </a>",
"      ]. Each of these agents may be used in children at",
"      <span class=\"nowrap\">",
"       age/weight-appropriate",
"      </span>",
"      doses. In some patients, a combination of two or more H1 antihistamines or doubling the dose of a nonsedating agent may provide better symptom control than the use of a single agent.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       Diphenhydramine",
"      </a>",
"      (25 to 50 mg QID) may be added on an as-needed basis to manage breakthrough symptoms.",
"     </li>",
"     <li>",
"      H2 antihistamines can be helpful for patient with hyperacidity and other gastrointestinal symptoms. Specific agents include oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      (adult dosing) (150 mg every 12 hours),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/45/728?source=see_link\">",
"       famotidine",
"      </a>",
"      (10 mg every 12 hours), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      (400 mg twice daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/26\">",
"       26",
"      </a>",
"      ]. Ranitidine and famotidine may be used in children at",
"      <span class=\"nowrap\">",
"       age/weight",
"      </span>",
"      appropriate doses.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33024?source=see_link\">",
"       Ketotifen",
"      </a>",
"      , which has been reported to have both mast cell stabilizing and H1 antihistamine properties, benefits patients with an array of mast cell activation symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/27\">",
"       27",
"      </a>",
"      ]. Where available in an oral preparation (eg, Canada and Europe), the adult dose is 1 to 4 mg orally every 12 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/28\">",
"       28",
"      </a>",
"      ]. Ketotifen may be used in children at",
"      <span class=\"nowrap\">",
"       age/weight",
"      </span>",
"      appropriate doses. Ketotifen can be quite sedating for some patients and they should be cautioned about this side effect.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"       Cromolyn sodium",
"      </a>",
"      stabilizes mast cell and eosinophil membranes in vitro, and its oral formulation (Gastrocrom) is helpful in some patients with gastrointestinal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/29\">",
"       29",
"      </a>",
"      ]. Dosing of the oral solution (100 to 200 mg per dose) is up to four times daily, although treatment should be initiated at the lower end of the dose range and gradually increased, as it is minimally absorbed through the intestine and can cause osmotic diarrhea if introduced at high doses.",
"     </li>",
"     <li>",
"      Anti-leukotriene agents may be added in patients with bronchospasm, flushing, itching, and abdominal cramping unresponsive to H1 and H2 antihistamines [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/30\">",
"       30",
"      </a>",
"      ]. Specific agents (adult dosing) include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      (10 mg daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      (20 mg daily), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"       zileuton",
"      </a>",
"      (1200 mg twice daily).",
"     </li>",
"     <li>",
"      Daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy may be considered in patients with flushing that is not responsive to other agents,",
"      <strong>",
"       if",
"      </strong>",
"      that patient does not have a contraindication to NSAID therapy (such as gastric ulcers),",
"      <strong>",
"       and",
"      </strong>",
"      if NSAIDs do not themselves trigger symptoms of mast cell activation when taken intermittently. If the patient's tolerance of aspirin is not known, the first dose of aspirin should be administered in a supervised setting to ensure that symptoms are not induced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4038188\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic criteria for monoclonal mast cell activation syndrome (MMAS) and mast cell activation syndrome (MCAS) have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These have been prospectively studied in a small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11401649\">",
"    <span class=\"h2\">",
"     MMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMAS is a histopathologic diagnosis supported by clinical findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs and symptoms consistent with mast cell activation, involving at least two organ systems. (See",
"      <a class=\"local\" href=\"#H4290513\">",
"       'Clinical manifestations of mast cell activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence of systemic mast cell mediator release, corresponding temporally to the presence of symptoms. (See",
"      <a class=\"local\" href=\"#H5002284\">",
"       'Document mast cell mediator release'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Failure to meet the",
"      <strong>",
"       major",
"      </strong>",
"      criterion for systemic mastocytosis, which is the demonstration of multifocal mast cell clusters of atypical (spindle-shaped) morphology in a bone marrow biopsy specimen and absence of cutaneous findings of mastocytosis (ie, urticaria pigmentosa, telangiectasia macularis eruptiva perstans, or mastocytomas). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\", section on 'Bone marrow studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fulfillment of",
"      <strong>",
"       one or two",
"      </strong>",
"      of the",
"      <strong>",
"       minor",
"      </strong>",
"      criteria for clonality for systemic mastocytosis, which are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mutational analysis of KIT showing a codon 816 mutation (eg, Asp816Val) in bone marrow, blood, or extracutaneous organs.",
"     </li>",
"     <li>",
"      Bone marrow or other extracutaneous mast cells expressing the surface markers CD2, CD25, or both.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Response to medications that inhibit the actions of mast cell mediators can be considered further supporting evidence for the diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11401677\">",
"    <span class=\"h2\">",
"     MCAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic MCAS is diagnosis of exclusion. Diagnostic criteria are similar to MMAS but do not include clonal histopathologic markers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4038445\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders that can present similarly to MMAS or MCAS are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4038452\">",
"    <span class=\"h2\">",
"     Systemic mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary disorder in the differential of MCAS is systemic mastocytosis. As mentioned previously, systemic mastocytosis is a clonal neoplastic disorder of the mast cell and should be diagnosed according to the World Health Organization's (WHO) criteria and NOT based upon symptoms alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4038459\">",
"    <span class=\"h2\">",
"     Cutaneous forms of mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous mastocytosis (CM) describes several forms of mastocytosis that are limited to the skin, without involvement of other organs. However, patients with CM may have episodes of mediator release that cause systemic symptoms. Serum tryptase and urinary histamine are usually normal, although they may be elevated when the skin is diffusely involved, such as in bullous forms or diffuse cutaneous mastocytosis. The presence of abnormal skin findings is critical to the diagnosis. Patients with cutaneous mastocytosis generally experience onset of lesions during infancy. Adult onset skin lesions of urticaria pigmentosa are generally associated with systemic mastocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4038466\">",
"    <span class=\"h2\">",
"     Idiopathic anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical criteria for the diagnosis of anaphylaxis have been defined (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"UTD.htm?22/43/23228\">",
"     table 4",
"    </a>",
"    ). Patients with anaphylaxis may have elevations of serum beta (mature) tryptase during (or for several hours after) acute events. In contrast, patients with systemic mastocytosis have persistent elevations in total tryptase in the baseline state. Patients with hymenoptera anaphylaxis and elevated random tryptase should be evaluated for systemic mastocytosis, regardless of the results of testing for hymenoptera sensitization.",
"   </p>",
"   <p>",
"    Idiopathic anaphylaxis is a diagnosis of exclusion, similar to mast cell activation syndrome. It is suggested that MCAS be assigned to patients whose symptoms do",
"    <strong>",
"     not",
"    </strong>",
"    meet the clinical definition of anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"UTD.htm?22/43/23228\">",
"     table 4",
"    </a>",
"    ), to distinguish MCAS from idiopathic anaphylaxis. If episodes do meet criteria for anaphylaxis, then the diagnosis of idiopathic anaphylaxis is more appropriate. The number of cases that remain idiopathic will most likely decrease as molecular studies of mast cells become more easily obtained and widely available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=see_link\">",
"     \"Idiopathic anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An approach to determining an underlying etiology in patients with anaphylaxis is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9401?source=see_link&amp;anchor=H4433858#H4433858\">",
"     \"Anaphylaxis: Confirming the diagnosis and determining the trigger(s)\", section on 'Testing for allergen trigger(s)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4038232\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with anaphylaxis should be supplied with an epinephrine autoinjector and instructed on how and when to use it.",
"   </p>",
"   <p>",
"    Drugs targeting mast cell mediators are the mainstay of prophylaxis and treatment of symptoms caused by MMAS and MCAS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/12\">",
"     12",
"    </a>",
"    ]. Those medications that were helpful to the patient during the diagnostic process should be continued at the lowest effective doses. The treatment of flushing and neuropsychiatric symptoms is discussed separately. (See",
"    <a class=\"local\" href=\"#H1092311\">",
"     'Assess response to anti-mediator treatment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prognosis of systemic mastocytosis\", section on 'Pharmacotherapy for all subtypes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone densitometry should be considered for patients with MMAS, as clonal mast cell disease is associated with osteoporosis. Treatment of osteoporosis in patients with mast cell disorders is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=see_link&amp;anchor=H10252967#H10252967\">",
"     \"Treatment and prognosis of systemic mastocytosis\", section on 'Osteoporosis and fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mast cell cytoreductive therapies such as IFN-alpha and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    are NOT appropriate for patients with symptoms of mast cell activation without diagnostic evidence of systemic mastocytosis or a clonal mast cell disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20937/abstract/31\">",
"     31",
"    </a>",
"    ]. The role of novel treatment modalities, such as anti-IgE or tyrosine kinase inhibitors remains investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4038297\">",
"    <span class=\"h1\">",
"     MONITORING AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yearly monitoring is appropriate for patients with MMAS or MCAS, although the frequency of evaluation should be increased if symptoms worsen or new symptoms appear. Tryptase levels and complete blood counts (with differential) are appropriate for most patients. Some cases of MMAS may progress to SM but more longitudinal follow-up data is needed. There is no evidence so far that MCAS progresses to a clonal form of mast cell disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1092715\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disorders of mast cells can be divided into three categories: primary, secondary, and idiopathic (",
"      <a class=\"graphic graphic_table graphicRef74166 \" href=\"UTD.htm?39/31/40443\">",
"       table 1",
"      </a>",
"      ). Within this schema, two previously unrecognized mast cell activation disorders have been recently distinguished: Monoclonal mast cell activation syndrome (MMAS) and mast cell activation syndrome (MCAS). (See",
"      <a class=\"local\" href=\"#H25846270\">",
"       'Classification of mast cell disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with MMAS and MCAS present with recurrent episodes suggestive of allergic reactions, with measurable increases in mast cell mediators associated with symptoms, but for which no consistent allergic cause has been identified. Symptoms are typically triggered by multiple factors, including eating, exertion, environmental conditions, emotional stress, or insect stings. In most cases, specific IgE-mediated allergies cannot be demonstrated or do not fully account for symptoms. (See",
"      <a class=\"local\" href=\"#H4290513\">",
"       'Clinical manifestations of mast cell activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with MMAS have episodes of mast cell activation symptoms, such as flushing, gastrointestinal cramping, and hypotension, similar to patients with systemic mastocytosis. However, unlike patients with mastocytosis, they lack urticaria pigmentosa, and baseline serum tryptase levels are usually normal or only slightly elevated. Clonal populations of mast cells can be demonstrated by c-kit point mutations and aberrant CD25 expression, although specialized techniques are sometimes required. Thus, patients with MMAS display one or two minor criteria for systemic mastocytosis but do not fully meet requirements for that diagnosis (",
"      <a class=\"graphic graphic_table graphicRef74223 \" href=\"UTD.htm?33/15/34044\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25846331\">",
"       'Monoclonal mast cell activation syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with MCAS also have recurrent episodes of mast cell activation symptoms, such as recurrent flushing and gastrointestinal cramping, but their episodes do not fulfill the diagnosis of anaphylaxis (",
"      <a class=\"graphic graphic_table graphicRef72225 \" href=\"UTD.htm?22/43/23228\">",
"       table 4",
"      </a>",
"      ). If symptoms are consistent with anaphylaxis, the diagnosis of idiopathic anaphylaxis is more appropriate. Patients with MCAS lack evidence of a monoclonal mast cell population (",
"      <a class=\"graphic graphic_table graphicRef74223 \" href=\"UTD.htm?33/15/34044\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25846353\">",
"       'Mast cell activation syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An evaluation for mast cell disorders is appropriate in a patient with manifestations of mast cell activation, such as flushing, urticaria, diarrhea, wheezing, fatigue or syncope or near syncope, affecting at least two organ systems. The diagnostic evaluation involves a detailed clinical history, physical examination to exclude signs or findings of other disorders, and laboratory studies (",
"      <a class=\"graphic graphic_algorithm graphicRef52981 \" href=\"UTD.htm?24/44/25280\">",
"       algorithm 1",
"      </a>",
"      ). The patient&rsquo;s response to medications that counter the effects of mast cell mediators is an important element of the diagnosis. (See",
"      <a class=\"local\" href=\"#H3576996\">",
"       'Diagnostic approach and algorithm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MCAS is a diagnosis of exclusion. Systemic mastocytosis and idiopathic anaphylaxis are the primary disorders that should be considered in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H4038445\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drugs targeting mast cell mediators are the mainstay of treatment of symptoms caused by MMAS and MCAS. Those medications that were helpful to the patient during the diagnostic process should be continued at the lowest effective doses. (See",
"      <a class=\"local\" href=\"#H1092311\">",
"       'Assess response to anti-mediator treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/1\">",
"      Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/2\">",
"      Sonneck K, Florian S, M&uuml;llauer L, et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2007; 142:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/3\">",
"      Ludolph-Hauser D, Ru&euml;ff F, Fries C, et al. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001; 357:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/4\">",
"      Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/5\">",
"      Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \"idiopathic\" anaphylaxis. Blood 2007; 110:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/6\">",
"      Akin C, Metcalfe DD. Occult bone marrow mastocytosis presenting as recurrent systemic anaphylaxis. J Allergy Clin Immunol 2003; 111:S206 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/7\">",
"      Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol 2010; 126:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/8\">",
"      Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012; 157:215.",
"     </a>",
"    </li>",
"    <li>",
"     Metcalfe DD. The mastocytosis syndrome. In: Fitzpatrick's dermatology in internal medicine, 5th ed, Freedburg IM, Eisen AZ, Wolff K, et aL (Eds), McGraw Hill, New York 1999. p.1902.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/10\">",
"      Koide T, Nakajima T, Makifuchi T, Fukuhara N. Systemic mastocytosis and recurrent anaphylactic shock. Lancet 2002; 359:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/11\">",
"      Kim DC, Horan R. Anaphylaxis to insect sting associated with urticaria pigmentosa. Allergy Asthma Proc 2003; 24:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/12\">",
"      Hamilton MJ, Hornick JL, Akin C, et al. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 2011; 128:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/13\">",
"      Haeberli G, Br&ouml;nnimann M, Hunziker T, M&uuml;ller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/14\">",
"      Metcalfe DD. Differential diagnosis of the patient with unexplained flushing/anaphylaxis. Allergy Asthma Proc 2000; 21:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/15\">",
"      Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004; 55:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/16\">",
"      Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/17\">",
"      Tetlow LC, Woolley DE. Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann Rheum Dis 1995; 54:896.",
"     </a>",
"    </li>",
"    <li>",
"     ImmunoCAP Tryptase, Phadia AB, Uppsala, Sweden. www.phadia.com (Accessed on May 24, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/19\">",
"      Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/20\">",
"      Alvarez-Twose I, Gonz&aacute;lez de Olano D, S&aacute;nchez-Mu&ntilde;oz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010; 125:1269.",
"     </a>",
"    </li>",
"    <li>",
"     In the United States, centers with expertise include the Brigham and Women's Hospital (Massachusetts), Mayo Clinic (Minnesota), Stanford University (California), and the National Institutes of Health (NIH) (Maryland). Other centers with expertise exist nationally and worldwide.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/22\">",
"      Akin C, Valent P, Escribano L. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr Allergy Asthma Rep 2006; 6:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/23\">",
"      Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006; 8:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/24\">",
"      Hahn HP, Hornick JL. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Am J Surg Pathol 2007; 31:1669.",
"     </a>",
"    </li>",
"    <li>",
"     N-methylhistamine in urine; and 11-beta-prostaglandin F2 alpha in urine are available commercially through Mayo Medical Laboratories. www.mayomedicallaboratories.com (Accessed on April 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/26\">",
"      Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000; 14:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/27\">",
"      Dykewicz MS, Wong SS, Patterson R, Harris KE. Evaluation of ketotifen in corticosteroid-dependent idiopathic anaphylaxis. Ann Allergy 1990; 65:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/28\">",
"      P&oacute;voa P, Ducla-Soares J, Fernandes A, Palma-Carlos AG. A case of systemic mastocytosis; therapeutic efficacy of ketotifen. J Intern Med 1991; 229:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/29\">",
"      Soter NA, Austen KF, Wasserman SI. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 1979; 301:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/30\">",
"      Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004; 350:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20937/abstract/31\">",
"      Escribano L, Akin C, Castells M, et al. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002; 81:677.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15715 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20937=[""].join("\n");
var outline_f20_28_20937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1092715\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5001792\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25846270\">",
"      CLASSIFICATION OF MAST CELL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25846317\">",
"      Primary mast cell disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25846324\">",
"      - Mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25846331\">",
"      - Monoclonal mast cell activation syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25846339\">",
"      Secondary mast cell activation disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25846346\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25846353\">",
"      - Mast cell activation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4290513\">",
"      CLINICAL MANIFESTATIONS OF MAST CELL ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1091266\">",
"      Provoking exposures and activities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4038003\">",
"      Specific organ systems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4290520\">",
"      - Skin and soft tissues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1091826\">",
"      Urticaria pigmentosa and other cutaneous lesions of mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4290527\">",
"      - Respiratory and naso-ocular",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4290534\">",
"      - Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4290541\">",
"      - Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4290548\">",
"      - Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4290562\">",
"      - Neuropsychiatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3576996\">",
"      DIAGNOSTIC APPROACH AND ALGORITHM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5002256\">",
"      Indications for evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H655017\">",
"      When to refer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5002263\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5002270\">",
"      Determine if urticaria pigmentosa is present",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1092166\">",
"      Determine baseline serum tryptase and need for bone marrow biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5299554\">",
"      - Bone marrow findings in MMAS and MCAS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15529537\">",
"      - The utility of other tissue biopsies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5002277\">",
"      Exclude allergic disease or other causes of secondary mast cell activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5002284\">",
"      Document mast cell mediator release",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1092311\">",
"      Assess response to anti-mediator treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4038188\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11401649\">",
"      MMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11401677\">",
"      MCAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4038445\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4038452\">",
"      Systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4038459\">",
"      Cutaneous forms of mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4038466\">",
"      Idiopathic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4038232\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4038297\">",
"      MONITORING AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1092715\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/15715\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15715|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/44/25280\" title=\"algorithm 1\">",
"      Approach to diagnosis of mast cell disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15715|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/49/41746\" title=\"picture 1\">",
"      Urticaria pigmentosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15715|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/31/40443\" title=\"table 1\">",
"      Classification of mast cell disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/15/34044\" title=\"table 2\">",
"      Comparison of mast cell disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/46/14059\" title=\"table 3\">",
"      Disorders with secondary mast cell activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/43/23228\" title=\"table 4\">",
"      Anaphylaxis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/37/41563\" title=\"table 5\">",
"      Possible triggers of mast cell activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/20/10572\" title=\"table 6\">",
"      Dx criteria for cutaneous and systemic mastocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9401?source=related_link\">",
"      Anaphylaxis: Confirming the diagnosis and determining the trigger(s)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12857?source=related_link\">",
"      Approach to flushing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=related_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38888?source=related_link\">",
"      Differential diagnosis of anaphylaxis in children and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=related_link\">",
"      Idiopathic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=related_link\">",
"      Mast cells: Surface receptors and signal transduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=related_link\">",
"      Treatment and prognosis of systemic mastocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_28_20938="Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations";
var content_f20_28_20938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20938/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20938/contributors\">",
"     Kapil Kumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20938/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20938/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20938/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/28/20938/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/28/20938/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/28/20938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with atrial fibrillation (AF), there are two main strategies to manage the irregular rhythm and its impact on symptoms: rhythm control (restoration followed by maintenance of sinus rhythm with either antiarrhythmic drugs or radiofrequency catheter ablation); and rate control with atrioventricular (AV) nodal blockers. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Rhythm versus rate control'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For those patients in whom a rhythm control strategy is chosen, the main goal of therapy is to reduce symptoms by decreasing the frequency and duration of episodes as well as the symptoms during recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As antiarrhythmic drugs are associated with a potential for serious adverse side effects, particularly the induction of proarrhythmia, they should be prescribed only by practitioners familiar with their use. Patients should be fully informed of both the benefits and risks associated with the use of these drugs. (See",
"    <a class=\"local\" href=\"#H523855015\">",
"     'Drug-related arrhythmias and mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Rhythm control can be achieved with either antiarrhythmic drug therapy or nonpharmacologic methods. This topic provides recommendations for the former. The clinical trials describing the efficacy and toxicity (including proarrhythmia) of the different antiarrhythmic drugs are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonpharmacologic methods to maintain sinus rhythm (including surgery and radiofrequency ablation) in selected patients who are refractory to conventional therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H577201755\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three settings in which a rhythm control strategy for the maintenance of sinus rhythm should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent symptoms (palpitations, dyspnea, lightheadedness, angina, syncope, and heart failure) despite adequate rate control.",
"     </li>",
"     <li>",
"      An inability to attain adequate rate control (to prevent tachycardia-mediated cardiomyopathy). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"       \"Tachycardia-mediated cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patient preference. Some patients will strongly prefer to avoid either paroxysmal or persistent AF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We consider cardioversion to sinus rhythm in most patients, particularly younger patients, with a first-detected episode of AF in whom the arrhythmia is of recent onset and the risk for recurrence appears to be low. Maintenance antiarrhythmic drug therapy is",
"    <strong>",
"     not",
"    </strong>",
"    routinely used after cardioversion in patients with newly detected AF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/3\">",
"     3",
"    </a>",
"    ]. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link&amp;anchor=H5422443#H5422443\">",
"     \"Rhythm control versus rate control in atrial fibrillation\", section on 'Newly detected AF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link\">",
"     \"Management of new onset atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523850664\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT DECISIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to selecting and initiating antiarrhythmic drug therapy, the following issues should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Rhythm versus rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice between a rhythm- or a rate-control strategy is determined by many factors, including patient age, the degree to which symptoms interfere with the quality of life, and concerns about antiarrhythmic drug therapy or radiofrequency catheter ablation.",
"   </p>",
"   <p>",
"    There is no evidence that long-term outcomes, such as rates of survival or thromboembolism, are improved by rhythm control (",
"    <a class=\"graphic graphic_figure graphicRef61608 \" href=\"UTD.htm?19/25/19870\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74434 \" href=\"UTD.htm?8/51/9022\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Our recommendations for the use of these two strategies are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link&amp;anchor=H5421057#H5421057\">",
"     \"Rhythm control versus rate control in atrial fibrillation\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523850711\">",
"    <span class=\"h2\">",
"     Addressing precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before initiating a rhythm control strategy, any risk factors for AF should be addressed. Examples include hyperthyroidism, hypertension, heart failure, and excess alcohol intake. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Disease associations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maintenance antiarrhythmic drug therapy is not recommended after cardioversion in a patient with a transient or reversible cause (such as cardiac surgery, pericarditis, or pulmonary embolism). An option in such patients is beta blocker therapy after restoration of sinus rhythm, which may provide modest protection against recurrent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/6\">",
"     6",
"    </a>",
"    ]. However, short-term antiarrhythmic therapy can be considered in this situation as the underlying cause is treated in patients who are highly symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523851008\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic anticoagulation is required with either rhythm or rate control in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. An exception to this need for maintenance anticoagulation occurs in patients without structural heart disease who are at low risk for embolization; such patients can be treated with no long-term antithrombotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, anticoagulation is required for at least three weeks prior to, during, and for at least four weeks after cardioversion in patients with AF duration of longer than 48 hours. After four weeks of anticoagulation, individuals who do not require long-term anticoagulation can discontinue the medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523851208\">",
"    <span class=\"h2\">",
"     AV nodal blocker therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An atrioventricular (AV) nodal blocker is usually started before, or simultaneously with, antiarrhythmic drug therapy in patients who have demonstrated a moderate to rapid ventricular rate (&ge;110 beats per minute) during AF. Slowing of the rate generally improves symptoms prior to the restoration of sinus rhythm. This therapy is continued while the patient is in sinus rhythm to protect against a rapid ventricular rate (greater than 110 bpm) should AF recur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A beta blocker, or rate-slowing calcium channel blocker such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , is often used if there are no contraindications, since the withdrawal of vagal tone and increase in sympathetic tone with exercise often render",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    relatively ineffective for controlling the heart rate. Beta blockers may be preferred, since they also modestly protect against recurrence of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Although verapamil may protect against AF-induced electrical remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/9-11\">",
"     9-11",
"    </a>",
"    ], it has not been shown to prevent recurrence of AF during long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is often used in patients with AF associated with systolic heart failure because of its beneficial effect on symptom control. Such patients are also typically treated with a beta blocker because of the associated improvement in survival. The negative inotropic activity of calcium channel blockers makes them less desirable in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, AV nodal blockade is useful to prevent a 1:1 response should atrial flutter occur after cardioversion or when class IA or IC drugs are used. Class I antiarrhythmic drugs (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , may suppress most, but not all, reentrant circuits. Although the atrial myocardium may not be capable of sustaining AF in this setting, it may be able to generate and sustain atrial flutter. In addition, the profound sodium channel blocking effects of the class IC drugs can markedly slow atrial conduction, making atrial flutter with 1:1 conduction a significant risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523851252\">",
"    <span class=\"h2\">",
"     Possible role of angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role of angiotensin inhibition to prevent recurrent AF is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20503?source=see_link&amp;anchor=H9#H9\">",
"     \"ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation\", section on 'Prevention of recurrent AF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H780615209\">",
"    <span class=\"h2\">",
"     Restoration of sinus rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with AF in whom a rhythm control strategy is chosen will need sinus rhythm restored prior to the initiation of long-term antiarrhythmic drug therapy. The restoration of sinus rhythm is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with relatively infrequent episodes of paroxysmal atrial fibrillation can be managed with antiarrhythmic therapy given only at the time of the episode. This form of outpatient \"pill-in-the-pocket\" therapy for recurrent AF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link&amp;anchor=H8701755#H8701755\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Antiarrhythmic drugs used in cardioversion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523850628\">",
"    <span class=\"h1\">",
"     SELECTING AN ANTIARRHYTHMIC DRUG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the issues discussed above have been addressed, an antiarrhythmic agent can be chosen. The choice of drug is significantly influenced both by drug and patient characteristics. As with all therapeutic interventions, the choice of agent should take into account the benefit to risk ratio of the therapy chosen. (See",
"    <a class=\"local\" href=\"#H523855022\">",
"     'Proarrhythmia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , and less commonly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    are the drugs we recommend to maintain sinus rhythm (",
"    <a class=\"graphic graphic_table graphicRef53499 \" href=\"UTD.htm?10/58/11180\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H58992353\">",
"     'Concerns about dronedarone'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For additional information regarding the therapeutic use of these drugs, including information regarding dosing and side effects, the reader is referred to individual UpToDate topics on these drugs or to the individual drug monographs in our drug database.",
"   </p>",
"   <p>",
"    The following points regarding antiarrhythmic drugs should be kept in mind in choosing therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to other agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is associated with the greatest likelihood of maintaining sinus rhythm, but also with the highest risk of long-term complications (",
"      <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"       \"Major side effects of amiodarone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       Quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      are no longer recommended for patients with AF, except perhaps in patients with vagally mediated AF (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=see_link&amp;anchor=H8804397#H8804397\">",
"       \"Mechanisms of atrial fibrillation\", section on 'Role of the autonomic nervous system'",
"      </a>",
"      ), as there are more effective drugs and due to extracardiac side effects as well as the concern about proarrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H523855022\">",
"       'Proarrhythmia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Beta blockers are modestly effective in maintaining sinus rhythm and can be tried first in selected patients, such as those without structural heart disease who are concerned about proarrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. Of course beta blockers may have already been initiated to slow the ventricular rate in AF. (See",
"      <a class=\"local\" href=\"#H523855022\">",
"       'Proarrhythmia'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link&amp;anchor=H20#H20\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Beta blockers'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following patient characteristics may influence decision making:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical features of the patient, such as presence or absence of clinical heart disease (",
"      <a class=\"graphic graphic_algorithm graphicRef64574 \" href=\"UTD.htm?42/48/43790\">",
"       algorithm 1A",
"      </a>",
"      ). We believe it is prudent to obtain a two-dimensional echocardiogram to screen for structural heart disease (eg, left ventricular systolic dysfunction, left ventricular hypertrophy, or valvular heart disease). An exercise or nuclear stress imaging test may be used to screen for coronary heart disease and is typically done before starting a class IC agent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'AF without structural heart disease'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H10\">",
"       'AF associated with structural heart disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The presence of paroxysmal compared to persistent AF [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/1,12\">",
"       1,12",
"      </a>",
"      ]. As examples, our experts rarely use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      for paroxysmal AF and infrequently choose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      for persistent AF due to reduced efficacy compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The presence of vagally-mediated AF [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. The 2010 European Society of Cardiology and the 2006 American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart",
"      <span class=\"nowrap\">",
"       Association/European",
"      </span>",
"      Society of Cardiology guidelines suggest that, because of its long-lasting anticholinergic activity,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      may be considered in patients with vagally-induced AF (eg, occurring most often in athletic young men with slow heart rates during rest or sleep), as long as the patient does not have prostatism or glaucoma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/12,18\">",
"       12,18",
"      </a>",
"      ]. The combination of disopyramide and either a beta blocker or a calcium channel blocker must be used cautiously because of the additive negative inotropic effects. If disopyramide cannot be given or is not tolerated,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      represent the sequential alternatives.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       Propafenone",
"      </a>",
"      is not recommended because its weak intrinsic beta blocking activity may aggravate vagally-induced paroxysmal AF. Our experts use disopyramide cautiously due to concern for proarrhythmia.",
"     </li>",
"     <li>",
"      For patients with adrenergically-mediated AF (eg, occurring during exercise or other activity), we suggest beta blockers as first-line therapy, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antiarrhythmic drugs are associated with a potential for serious adverse side effects, particularly the induction of proarrhythmia. Thus, they should be prescribed only by practitioners familiar with their use. Patients should be fully informed of both the benefits and risk associated with the use of these drugs. (See",
"    <a class=\"local\" href=\"#H523855015\">",
"     'Drug-related arrhythmias and mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As the expectation of antiarrhythmic therapy is to reduce the frequency and duration of episodes, improve quality of life, and prevent hospitalization, a recurrence of AF does not necessarily denote a failure of the medication or mandate a change to a different antiarrhythmic drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     AF without structural heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without structural heart disease include those with hypertension who do not have left ventricular hypertrophy. The author and reviewers of this topic generally select",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    as the first antiarrhythmic drug for these patients due to its relatively good side effect profile, efficacy, and ease of use.",
"   </p>",
"   <p>",
"    In these patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    are superior to placebo for maintaining sinus rhythm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those patients in whom",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    will not be used as the preferred agent, the following points can influence the choice of antiarrhythmic drug in patients without structural heart disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Canadian Trial of Atrial fibrillation, AFFIRM, and the SAFE-T randomized trials,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      was more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      (which have nearly equivalent efficacy to each other), but has a significantly higher rate of adverse side effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link&amp;anchor=H12#H12\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Amiodarone'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a meta-analysis of trials where the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      was estimated with the use of indirect comparison and normal logistic meta-analysis models, amiodarone was found to be more effective in maintaining sinus rhythm, but at the expense of greater drug discontinuation secondary to adverse events [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link&amp;anchor=H17#H17\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Dronedarone'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Both amiodarone and dronedarone are associated with significant side effects. We suggest carefully discussing these with the patient prior to initiating therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12745?source=see_link&amp;anchor=H155067#H155067\">",
"       \"Clinical uses of dronedarone\", section on 'Adverse effects'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"       \"Major side effects of amiodarone\"",
"      </a>",
"      .)In the EMERALD trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      had a somewhat better efficacy than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link&amp;anchor=H15#H15\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Dofetilide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       Propafenone",
"      </a>",
"      may have less proarrhythmia than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H523855022\">",
"       'Proarrhythmia'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link&amp;anchor=H10#H10\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Class IC antiarrhythmic drugs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some cardiologists prefer to use low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (200 mg per day) in preference to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    for two principal reasons: greater efficacy than sotalol and dronedarone (",
"    <a class=\"graphic graphic_figure graphicRef69285 \" href=\"UTD.htm?4/48/4878\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/20-22\">",
"     20-22",
"    </a>",
"    ], and a very low incidence of torsades de pointes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In addition, since amiodarone has beta blocking and calcium channel blocking activity, the ventricular rate is usually slower and better tolerated if AF does recur. If amiodarone is used for rhythm control, the need for additional medications to control rate (eg, beta blockers or calcium channel blockers) may be decreased. Despite these advantages, low-dose amiodarone still has appreciable toxicity, including thyroid disease, hepatic dysfunction, lung disease, neurologic abnormalities, and bradycardia (",
"    <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     AF associated with structural heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    are the most commonly recommended first-line drugs in patients with structural heart disease (",
"    <a class=\"graphic graphic_algorithm graphicRef64574 graphicRef83173 \" href=\"UTD.htm?15/17/15633\">",
"     algorithm 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/12\">",
"     12",
"    </a>",
"    ]. Our authors and reviewers prefer either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    or sotalol to amiodarone and dofetilide. Dronedarone is easier to use than sotalol (continuous monitoring of initiation required), but is less efficacious. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These drugs (with the exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    ) were used for initial therapy in almost 70 percent of patients in AFFIRM, 88 percent of whom had organic heart disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    was significantly more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    in the CTAF, AFFIRM, and SAFE-T trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. However, in SAFE-T, sotalol was as effective as amiodarone in the subgroup of patients with coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with coronary heart disease who do not have heart failure,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    are acceptable choices (",
"    <a class=\"graphic graphic_table graphicRef66133 \" href=\"UTD.htm?19/15/19708\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef64574 \" href=\"UTD.htm?42/48/43790\">",
"     algorithm 1A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/12,25,26\">",
"     12,25,26",
"    </a>",
"    ]. We prefer sotalol due to its better extracardiac side effect profiles.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     Flecainide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    are contraindicated in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=see_link\">",
"     \"Major side effects of class I antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the Cardiac Arrhythmia Suppression Trial (CAST) of patients with drug-suppressible ventricular premature beats in the year following a myocardial infarction,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    increased mortality compared to placebo (",
"    <a class=\"graphic graphic_figure graphicRef59975 \" href=\"UTD.htm?19/4/19534\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/27\">",
"     27",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    was not used in CAST and may not have the same potential for proarrhythmia as flecainide and encainide [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/28\">",
"     28",
"    </a>",
"    ], it cannot be recommended in patients with underlying heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extension of this concern to structural heart disease other than coronary artery disease stems in part from the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    clinical and safety database, which was used in a retrospective study demonstrating that the presence of structural heart disease including valvular heart disease, congenital heart disease, and cardiomyopathies lead to an alarming increase in proarrhythmia and death [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , are used in patients with AF and HF or those with a left ventricular ejection fraction less than 35 percent. Our authors and reviewers are more comfortable using dofetilide in this setting with an implantable defibrillator in place or in younger patients with less severe impairment of left ventricular systolic function. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    should not be used in patients with heart failure, due to studies showing an increase in mortality with these agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=see_link\">",
"     \"Major side effects of class I antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with significant left ventricular hypertrophy (defined as left ventricular wall thickness greater 1.4 cm for the purposes of this discussion) due to hypertension, hypertrophic cardiomyopathy, or aortic stenosis have underlying subendocardial ischemia and electrophysiologic abnormalities. These increase the risk for proarrhythmia with antiarrhythmic agents (",
"    <a class=\"graphic graphic_algorithm graphicRef64574 \" href=\"UTD.htm?42/48/43790\">",
"     algorithm 1A",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1401?source=see_link\">",
"     \"Left ventricular hypertrophy and arrhythmia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H523855022\">",
"     'Proarrhythmia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    are thought to have a significant arrhythmic risk in patients with left ventricular hypertrophy (LVH).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     Dronedarone",
"    </a>",
"    has been evaluated in patients with LVH and is thought to be relatively safe [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/26\">",
"     26",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is another therapeutic option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12745?source=see_link\">",
"     \"Clinical uses of dronedarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Drug-resistant AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients are refractory to individual antiarrhythmic agents plus an AV nodal blocker or develop side effects on doses necessary for arrhythmia prevention. Although some have suggested that combination antiarrhythmic drug therapy (eg, a class IC agent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , often in lower doses) may be an alternative, there are limited data to support such an approach and the patient may be exposed to a greater risk of proarrhythmia and other side effects.",
"   </p>",
"   <p>",
"    As a result, combination antiarrhythmic drug therapy is not recommended. Such patients can be treated with a rate control strategy or referred for nonpharmacologic therapy to prevent recurrent AF including surgery (such as the maze operation) or radiofrequency ablation (such as pulmonary vein isolation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5367?source=see_link\">",
"     \"The role of pacemakers in the prevention of atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425527372\">",
"    <span class=\"h1\">",
"     INPATIENT VERSUS OUTPATIENT INITIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients begun on antiarrhythmic drug therapy should be hospitalized for continuous electrocardiographic monitoring due to a 10 to 15 percent incidence of adverse cardiac events during the initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H523855022\">",
"     'Proarrhythmia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33223?source=see_link&amp;anchor=H11#H11\">",
"     \"Arrhythmia management for the primary care clinician\", section on 'Antiarrhythmic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two complications of greatest concern are bradycardia and proarrhythmia. Other adverse cardiac events can include significant QT prolongation, heart failure, rapid ventricular rate, conduction abnormalities, hypotension, and stroke. The risk is greatest in the first 24 hours and in patients with a prior myocardial infarction.",
"   </p>",
"   <p>",
"    Outpatient initiation of antiarrhythmic drug therapy with the following agents may be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       Flecainide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      in patients in sinus rhythm who have no underlying structural heart disease, normal baseline QT intervals, and no profound bradycardia or suspected sinus or AV node dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      in selected patients who have no other risk factors for torsades de pointes (eg, hypokalemia, hypomagnesemia) or sinus node dysfunction or AV conduction disease. Dronedarone and amiodarone are the only two drugs that can be initiated in outpatients while in atrial fibrillation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with an implantable cardioverter-defibrillator (ICD) represent another group in which outpatient initiation of therapy can be tried, since the ICD provides protection against the risks associated with bradyarrhythmias and tachyarrhythmias. However, one should be cognizant of the potential effects of antiarrhythmic drugs on ventricular defibrillation threshold and ventricular tachycardia cycle length, which could influence the efficacy of ICD therapy.",
"   </p>",
"   <p>",
"    The initiation of antiarrhythmic drugs in patients with paroxysmal AF while they are in sinus rhythm is also associated with some risk. In a review of 409 outpatient initiation trials for a history of recurrent AF or atrial flutter, adverse cardiac events occurred in 17 (4.5 percent); these included three deaths, three permanent pacemakers for bradycardia, and 11 dose reductions for bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inpatient initiation with continuous telemetry of higher-risk drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    is typically done over a course of three days, which encompasses five half-lives allowing for achievement of steady-state plasma concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523854472\">",
"    <span class=\"h1\">",
"     LONG-TERM ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H577202428\">",
"    <span class=\"h2\">",
"     AF recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent AF should not necessarily be labeled as treatment failure. Some patients will elect to continue drug therapy (and, in some cases, occasional cardioversion) because the arrhythmia burden has been substantially reduced as evidenced by episodes that are less frequent, shorter, or associated with milder symptoms. Nonpharmacologic therapies are another option in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a patient has unacceptable recurrent AF on one antiarrhythmic drug, the drug is discontinued and another (and on rare occasion a third) agent is tried.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523854907\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The starting and maintenance doses for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    are found in respective LexiComp drug monographs available in UpToDate. Many factors including age, sex, weight, renal or hepatic function, and characteristics on the electrocardiogram influence the starting dose for many of these. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523855015\">",
"    <span class=\"h2\">",
"     Drug-related arrhythmias and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antiarrhythmic drugs is associated with possible life-threatening side effects. The greatest concerns with these agents are proarrhythmia (and consequent tachyarrhythmia) and bradycardia. Patients should be instructed to report symptoms suggestive of the development of drug related arrhythmias, such as syncope, lightheadedness or dizzy spells, or worsening exercise intolerance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33223?source=see_link&amp;anchor=H11#H11\">",
"     \"Arrhythmia management for the primary care clinician\", section on 'Antiarrhythmic drugs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33223?source=see_link&amp;anchor=H6#H6\">",
"     \"Arrhythmia management for the primary care clinician\", section on 'Symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2012 meta-analysis of 56 studies (20,771 patients) compared one or more antiarrhythmic drugs to control or to each other [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/33\">",
"     33",
"    </a>",
"    ]. Compared to controls, the use of the class IA antiarrhythmics",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    (odds ratio 2.39, 95% CI 1.03-5.59) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    (2.47, 95% CI 1.2-5.05) was associated with increased all-cause mortality, whereas the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    was not (odds ratios were not calculated for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ). All antiarrhythmics studied showed increased pro-arrhythmic effects (counting both bradyarrhythmias and tachyarrhythmias attributable to treatment), with the exceptions of amiodarone, dronedarone, and propafenone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523855022\">",
"    <span class=\"h3\">",
"     Proarrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the antiarrhythmic drugs used to maintain sinus rhythm have the potential to increase ectopy or induce or aggravate monomorphic ventricular tachycardia (VT), torsades de pointes, or ventricular fibrillation (VF); this is referred to as proarrhythmia (",
"    <a class=\"graphic graphic_table graphicRef66133 \" href=\"UTD.htm?19/15/19708\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to its baseline potential to predispose the patient to proarrhythmia, a drug that is initially safe may become proarrhythmic when the patient develops coronary heart disease or heart failure or is treated with other medications that in combination may be arrhythmogenic. Thus, the patient should be alerted to the potential significance of symptoms such as syncope and dyspnea and warned about the use of noncardiac drugs that can prolong the QT interval (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the following recommendations made according to drug class in the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology guideline [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With type IC drugs, QRS widening should not be permitted to exceed 150 percent of the baseline QRS duration. Exercise testing may detect QRS widening that occurs only at rapid heart rates (use-dependent conduction slowing). Exercise testing is also a useful way to screen for exercise-induced proarrhythmia and is typically performed one to two weeks after drug initiation.",
"     </li>",
"     <li>",
"      For type IA or type III drugs (",
"      <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"       table 1",
"      </a>",
"      ), with the possible exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , the corrected QT interval in sinus rhythm should remain below 520 milliseconds. More specific and conservative recommendations are available for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      in the package insert. (See",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       \"Dofetilide: Drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      During follow-up, serum creatinine, potassium, and magnesium concentrations should be monitored periodically because proarrhythmia is increased by renal insufficiency, which can lead to drug accumulation, hyperkalemia, and hypermagnesemia. The presence of renal insufficiency warrants dose reduction or cessation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      . In comparison,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is metabolized in the liver and dose adjustment is probably necessary in patients with hepatic dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link&amp;anchor=H11#H11\">",
"       \"Major side effects of amiodarone\", section on 'Hepatotoxicity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523855029\">",
"    <span class=\"h3\">",
"     Bradyarrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    can cause both sinus bradycardia and AV nodal block, with an overall incidence of bradycardic events of about 5 percent.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    , like other beta blockers, can also cause bradycardia. In some cases, permanent pacemaker placement is necessary to permit continued use of these agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519908970\">",
"    <span class=\"h3\">",
"     Ambulatory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our authors and reviewers have differing thresholds for the use of ambulatory monitoring to screen for proarrhythmia and bradycardia, ranging from screening in the highest risk cases only to screening in everyone. Some experts suggest screening all patients with an ambulatory event monitor for at least two weeks after initiation of therapy, looking for QT interval prolongation or bradyarrhythmias. The basis for this recommendation is that many events occur after three days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/32\">",
"     32",
"    </a>",
"    ]. For those experts who are more selective based on patient risk, high-risk is defined as baseline bradycardia or borderline QT prolongation, heart failure, or systolic left ventricular dysfunction. Others perform routine monitoring when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    are chosen.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    must be initiated in a setting with continuous monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=see_link\">",
"     \"Therapeutic use of dofetilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those patients who are not referred for ambulatory monitoring, we suggest that a 12-lead electrocardiogram be obtained after the initiation of antiarrhythmic drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266072426\">",
"    <span class=\"h2\">",
"     Short- versus long-term therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on concerns about drug related arrhythmias and the observation that the atrial action potential normalizes after two to four weeks of sinus rhythm (after AF), the concept that short-term therapy might be as effective and safer than long-term therapy has been proposed. This concept was tested in the Flec-SL non-inferiority trial, which randomly assigned 554 patients with persistent AF and who were intended to undergo cardioversion to either four weeks or six months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    (200 to 300 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/34\">",
"     34",
"    </a>",
"    ]. All patients had successful restoration of sinus rhythm and were then followed with daily telemetric electrocardiography (and Holter monitoring whenever AF was noted on two ECGs) for six months.",
"   </p>",
"   <p>",
"    The primary outcome of time to persistent AF or death occurred in 46 and 39 percent of patients, respectively, which did not meet the criteria of non-inferiority. In addition, a post-hoc analysis of patients who had not reached the primary endpoint in the first month found long-term therapy to be superior (Kaplan-Meier estimate of difference 14.3 percent; hazard ratio 0.3; p = 0.0001). We do not consider short-term therapy appropriate for most patients with persistent AF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58992353\">",
"    <span class=\"h2\">",
"     Concerns about dronedarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe HF (generally those with NYHA class III or IV HF, or those who have been hospitalized with HF in the past four weeks) or those with an ejection fraction of &lt;35 percent should not receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link&amp;anchor=H19977042#H19977042\">",
"     \"Atrial fibrillation in patients with heart failure\", section on 'Dronedarone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Permanent Atrial fibriLLAtion outcome Study (PALLAS) was designed to test the hypothesis that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    would improve major outcomes in 10,000 patients with permanent AF, over 70 percent of whom had New York Heart Association heart failure class I to III or left ventricular systolic dysfunction at baseline. The rationale was that patients with permanent AF, which affects up to 50 percent of patients with AF, have an increased risk of adverse cardiovascular outcomes including death and myocardial infarction as well as systemic embolization. The ATHENA trial showed a significant reduction in cardiovascular events with dronedarone in patients with paroxysmal or persistent AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link&amp;anchor=H17#H17\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Dronedarone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients in PALLAS were treated with standard therapies for AF and then randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    or placebo. The study was stopped early (3236 patients enrolled), after a significantly increased risk (Hazard Ratio 2.29, 95% CI 1.34-3.94) of cardiovascular events (cardiovascular death, myocardial infarction, stroke and systemic embolism) was observed in the dronedarone arm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/35\">",
"     35",
"    </a>",
"    ]. The individual secondary end points of stroke, death from cardiovascular causes, and hospitalization for heart failure were also significantly increased in the dronedarone group. (See",
"    <a class=\"local\" href=\"#H5304343\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)&nbsp;",
"   </p>",
"   <p>",
"    The European Medicines Agency and the United States Food and Drug Agency (USFDA) have advised against the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    in patients with permanent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In addition, the USFDA now recommends that people taking the drug should have an electrocardiogram every three months to make sure that AF has not become permanent. For patients taking dronedarone, routine monitoring of lung and liver function is not mandated by the USFDA; however, periodic monitoring may be reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12745?source=see_link&amp;anchor=H155067#H155067\">",
"     \"Clinical uses of dronedarone\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523850780\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations for the use of antiarrhythmic drugs to maintain sinus rhythm in patients with AF are generally in agreement with the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines on AF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/12\">",
"     12",
"    </a>",
"    ] and the 2010 European Society of Cardiology guidelines on AF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5304343\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    as first-line drugs to maintain sinus rhythm after cardioversion in patients without structural heart disease;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    can also be given as second-line agents (",
"    <a class=\"graphic graphic_algorithm graphicRef83173 \" href=\"UTD.htm?35/57/36766\">",
"     algorithm 1B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/12\">",
"     12",
"    </a>",
"    ]. The 2010 ESC guidelines and the",
"    <span class=\"nowrap\">",
"     ACC/AHA/Heart",
"    </span>",
"    Rhythm Society (HRS) 2011 focused update on atrial fibrillation management have added",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    as another alternative first-line agent (",
"    <a class=\"graphic graphic_algorithm graphicRef64574 \" href=\"UTD.htm?42/48/43790\">",
"     algorithm 1A",
"    </a>",
"    ). These drugs are generally better tolerated and perhaps safer than the class IA drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , which were widely used in the past.",
"   </p>",
"   <p>",
"    Because of concerns about toxicity, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines recommend that the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    as a first-line therapy for maintenance of sinus rhythm should be reserved for patients with heart failure, moderate-to-severe systolic dysfunction, or hypertension with substantial left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/36/17986?source=see_link\">",
"       \"Patient information: Medicines for atrial fibrillation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5304343\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those patients with atrial fibrillation (AF) in whom a rhythm-control strategy is chosen, the principal goal is to reduce symptoms by decreasing the frequency and duration of episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/28/20938/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Rhythm versus rate control'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Prior to selecting and initiating antiarrhythmic drug therapy, issues of precipitating factors, anticoagulation, and rate control should be addressed. (See",
"    <a class=\"local\" href=\"#H523850711\">",
"     'Addressing precipitating factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H523851008\">",
"     'Anticoagulation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H523851208\">",
"     'AV nodal blocker therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following points should be kept in mind when considering antiarrhythmic drug therapy to maintain sinus rhythm in patients with AF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers are modestly effective in maintaining sinus rhythm and can be tried first in selected patients, such as those without structural heart disease who are concerned about proarrhythmia. (See",
"      <a class=\"local\" href=\"#H523850628\">",
"       'Selecting an antiarrhythmic drug'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared to placebo,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      are effective for the maintenance of sinus rhythm, but maintenance rates at one year are significantly less than 75 percent. Amiodarone is consistently more effective than the other antiarrhythmic drugs. (See",
"      <a class=\"local\" href=\"#H523850628\">",
"       'Selecting an antiarrhythmic drug'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The primary-efficacy endpoint of most clinical trials involving antiarrhythmic drugs has been time to first recurrence of AF or percent of patients in sinus rhythm at the end of one year. However, there is great variation in efficacy of antiarrhythmic drugs from patient to patient. Although a drug may be shown to significantly prolong the time to recurrence of AF in a clinical trial, individual patients may experience no benefit or experience a dramatic reduction in AF frequency. Also, a single recurrence of AF on an antiarrhythmic drug does not necessarily indicate treatment failure or require a change in therapy. (See",
"      <a class=\"local\" href=\"#H523854472\">",
"       'Long-term issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to less-than-optimal efficacy, serious drug-related adverse side effects limit the use of these drugs. Antiarrhythmic drug therapy should be prescribed only by practitioners familiar with their use. Patients should be fully informed of both the benefits and risks associated with the use of these drugs. (See",
"      <a class=\"local\" href=\"#H523855015\">",
"       'Drug-related arrhythmias and mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based upon the potential for drug toxicity in the form of induced bradycardia or tachycardia, many patients will need to be hospitalized for continuous electrocardiographic monitoring.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      must be initiated in a setting with continuous monitoring. (See",
"      <a class=\"local\" href=\"#H425527372\">",
"       'Inpatient versus outpatient initiation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We make the following recommendations for the choice of antiarrhythmic drug to maintain sinus rhythm in patients with AF (see",
"    <a class=\"local\" href=\"#H523850628\">",
"     'Selecting an antiarrhythmic drug'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with no structural heart disease and no apparent risk for drug-induced bradycardia or tachycardia, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      as the preferred antiarrhythmic drug (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      may be used, with the latter two chosen more often by our authors and reviewers. Practitioners should choose only those agents with which they have significant familiarity. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'AF without structural heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with coronary artery disease who do not have advanced heart failure, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      in preference to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Amiodarone is a reasonable choice in patients who prefer its greater efficacy despite its worse extracardiac side-effect profile. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with heart failure, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      in preference to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       Flecainide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      are contraindicated in these patients. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with left ventricular hypertrophy, either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      is generally preferred to other antiarrhythmic agents. Our authors and reviewers have differing approaches, with some choosing amiodarone more often and others choosing dronedarone more often. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Left ventricular hypertrophy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the initiation of antiarrhythmic drug therapy, screening for drug-associated arrhythmia with ambulatory monitoring should be considered, particularly for patients at high risk of drug-induced arrhythmia. This includes those with baseline bradycardia or borderline QT prolongation, heart failure, or systolic left ventricular dysfunction. (See",
"    <a class=\"local\" href=\"#H519908970\">",
"     'Ambulatory monitoring'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/1\">",
"      Falk RH. Atrial fibrillation. N Engl J Med 2001; 344:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/2\">",
"      Connolly SJ. Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. Am Heart J 2000; 139:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/3\">",
"      Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003; 139:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/4\">",
"      Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/5\">",
"      Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/6\">",
"      K&uuml;hlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000; 36:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/7\">",
"      Steeds RP, Birchall AS, Smith M, Channer KS. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 1999; 82:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/8\">",
"      Plewan A, Lehmann G, Ndrepepa G, et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J 2001; 22:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/9\">",
"      Tieleman RG, De Langen C, Van Gelder IC, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997; 95:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/10\">",
"      Daoud EG, Knight BP, Weiss R, et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997; 96:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/11\">",
"      Bertaglia E, D'Este D, Zerbo F, et al. Effects of verapamil and metoprolol on recovery from atrial electrical remodeling after cardioversion of long-lasting atrial fibrillation. Int J Cardiol 2003; 87:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/12\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/13\">",
"      McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/14\">",
"      Lafuente-Lafuente C, Mouly S, Long&aacute;s-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006; 166:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/15\">",
"      Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/16\">",
"      Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 1996; 7:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/17\">",
"      Herweg B, Dalal P, Nagy B, Schweitzer P. Power spectral analysis of heart period variability of preceding sinus rhythm before initiation of paroxysmal atrial fibrillation. Am J Cardiol 1998; 82:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/18\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/19\">",
"      Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009; 54:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/20\">",
"      Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/21\">",
"      Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/22\">",
"      AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/23\">",
"      Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/24\">",
"      Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/25\">",
"      Zimetbaum P, Josephson ME. Is there a role for maintaining sinus rhythm in patients with atrial fibrillation? Ann Intern Med 2004; 141:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/26\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/27\">",
"      Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/28\">",
"      Podrid PJ, Anderson JL. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. Am J Cardiol 1996; 78:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/29\">",
"      Podrid PJ, Lampert S, Graboys TB, et al. Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors. Am J Cardiol 1987; 59:38E.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/30\">",
"      Morganroth J, Anderson JL, Gentzkow GD. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol 1986; 8:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/31\">",
"      Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997; 127:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/32\">",
"      Hauser TH, Pinto DS, Josephson ME, Zimetbaum P. Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter. Am J Cardiol 2003; 91:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/33\">",
"      Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012; 5:CD005049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/34\">",
"      Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012; 380:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/28/20938/abstract/35\">",
"      Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011; 365:2268.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/09/news_detail_001344.jsp&amp;murl=menus/news_and_events/news_and_events.jsp&amp;mid=WC0b01ac058004d5c1.",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm264204.htm.",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm240011.htm.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1035 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C0D21FD3A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20938=[""].join("\n");
var outline_f20_28_20938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5304343\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H577201755\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523850664\">",
"      INITIAL MANAGEMENT DECISIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Rhythm versus rate control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523850711\">",
"      Addressing precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523851008\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523851208\">",
"      AV nodal blocker therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523851252\">",
"      Possible role of angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H780615209\">",
"      Restoration of sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523850628\">",
"      SELECTING AN ANTIARRHYTHMIC DRUG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AF without structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      AF associated with structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Drug-resistant AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H425527372\">",
"      INPATIENT VERSUS OUTPATIENT INITIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523854472\">",
"      LONG-TERM ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H577202428\">",
"      AF recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523854907\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523855015\">",
"      Drug-related arrhythmias and mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H523855022\">",
"      - Proarrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H523855029\">",
"      - Bradyarrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H519908970\">",
"      - Ambulatory monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266072426\">",
"      Short- versus long-term therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58992353\">",
"      Concerns about dronedarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523850780\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5304343\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1035\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1035|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/48/43790\" title=\"algorithm 1A\">",
"      Choosing an antiarrhythmic drug to prevent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/57/36766\" title=\"algorithm 1B\">",
"      Algorithm for the maintenance of sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1035|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/25/19870\" title=\"figure 1\">",
"      Rhythm versus rate control AF AFFIRM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/51/9022\" title=\"figure 2\">",
"      Rhythm versus rate control AF RACE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/48/4878\" title=\"figure 3\">",
"      Recurrent AF after amiodarone propafenone and sotalol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/4/19534\" title=\"figure 4\">",
"      Proarrhythmia with class Ic antiarrhythmic drugs in CAST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1035|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/58/11180\" title=\"table 2\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/11/5309\" title=\"table 3\">",
"      Side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/15/19708\" title=\"table 4\">",
"      Types of proarrhythmia of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 5\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20503?source=related_link\">",
"      ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33223?source=related_link\">",
"      Arrhythmia management for the primary care clinician",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12745?source=related_link\">",
"      Clinical uses of dronedarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=related_link\">",
"      Dofetilide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1401?source=related_link\">",
"      Left ventricular hypertrophy and arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=related_link\">",
"      Major side effects of class I antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=related_link\">",
"      Management of new onset atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=related_link\">",
"      Mechanisms of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/36/17986?source=related_link\">",
"      Patient information: Medicines for atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5367?source=related_link\">",
"      The role of pacemakers in the prevention of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=related_link\">",
"      Therapeutic use of dofetilide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_28_20939="Pregnancy loss rates after selective termination";
var content_f20_28_20939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pregnancy loss rates after selective termination by starting number, finishing number, and by number of fetuses reduced",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loss rates, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Starting number (n)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 (164)",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;3 (36)",
"       </td>",
"       <td>",
"        11.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Finishing number",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 (170)",
"       </td>",
"       <td>",
"        3.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;2 (30)",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Number of fetuses reduced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 (193)",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 (7)",
"       </td>",
"       <td>",
"        42.9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stone J, Eddleman K, Lynch L, Berkowitz RL. A single center experience with 1000 consecutive cases of multifetal pregnancy reduction. Am J Obstet Gynecol 2002; 187:1163. Copyright &copy; 2002 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20939=[""].join("\n");
var outline_f20_28_20939=null;
var title_f20_28_20940="Monitoring atyp antipsych";
var content_f20_28_20940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Monitoring protocol for patients on atypical antipsychotics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Baseline",
"      </td>",
"      <td class=\"subtitle1\">",
"       4 weeks",
"      </td>",
"      <td class=\"subtitle1\">",
"       8 weeks",
"      </td>",
"      <td class=\"subtitle1\">",
"       12 weeks",
"      </td>",
"      <td class=\"subtitle1\">",
"       Quarterly",
"      </td>",
"      <td class=\"subtitle1\">",
"       Annually",
"      </td>",
"      <td class=\"subtitle1\">",
"       Every 5 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Personal/family history",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Weight (BMI)",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Waist circumference",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blood pressure",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fasting plasma glucose",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fasting lipid profile",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    More frequent assessments may be warranted based on clinical status.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: American Diabetes Association. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004; 27:596. Copyright &copy;2004 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20940=[""].join("\n");
var outline_f20_28_20940=null;
var title_f20_28_20941="Nifedipine in AR";
var content_f20_28_20941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nifedipine delays progression of aortic regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 250px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative incidence of aortic valve replacement in patients with asymptomatic aortic regurgitation treated with digoxin or nifedipine. The rate of progression to valve replacement was significantly lower in the nifedipine group at all times after the first year (p = 0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Scognamiglio, R, Rahimtoola, SH, Fasolli, G, et al, N Engl J Med 1994; 331:689.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20941=[""].join("\n");
var outline_f20_28_20941=null;
var title_f20_28_20942="Ileocolic anastomosis - Stapled anastomosis reinforced";
var content_f20_28_20942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ileocolic anastomosis - Stapled anastomosis with reinforcing sutures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20942=[""].join("\n");
var outline_f20_28_20942=null;
var title_f20_28_20943="CBD stones MRCP II";
var content_f20_28_20943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common bile duct stones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRCP study, obtained in a 60-year-old woman with recurrent right upper quadrant pain and an unremarkable ultrasound examination, shows small stones (arrows) in the gallbladder (GB) and the common bile duct (CBD).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_28_20943=[""].join("\n");
var outline_f20_28_20943=null;
